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Abstract  
 
Breast cancer remains the most commonly diagnosed cancer in women. It is 
responsible for 32% of all cancers and 15% of all cancer-related deaths in females. 
Patients with triple-negative breast cancers (TNBC) constitute about one-fifth of all 
breast cancer patients. TNBC is an aggressive and heterogeneous disease entity in 
comparison with other types of breast cancer and, therefore, tends to be resistant to 
existing treatment regimens, such as, targeted and hormone therapies.  
 
Although cancer treatment has evolved from being invasive and highly toxic to being 
more specific with reduced normal tissue toxicity, intrinsic tumour resistance still 
limits the benefit of therapy with radiation, drugs, and antibodies. To address this 
important clinical challenge, attempts have been made to better understand the 
molecular determinants of treatment resistance. This resistance can be attributed to 
the heterogeneity in the distribution of potential target antigens in a given tumour cell 
population, which leads to the inability to effectively target all cells with toxic levels of 
a particular therapeutic agent.  
 
There is evidence to suggest that proliferative pathways of triple-negative tumours 
are still poorly understood, which could be the reason for the observed treatment 
resistance. Targeted treatment modalities that are singly effective for triple-negative 
breast cancer are lacking, partly due to paucity of relevant targets as they are devoid 
of the human epidermal growth factor receptor 2 (HER2), progesterone receptor 
(PR), and oestrogen receptor (ER). Novel treatment approaches are, therefore, 
needed to overcome the challenges in the treatment of triple-negative breast cancers 
if treatment outcomes are to be improved. Concomitant targeting of cell signalling 
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entities other than HER2, PR and ER may sensitise triple-negative tumours to 
radiotherapy.  
 
In this study, inhibition of HER2, phosphoinositide 3-kinase (PI3K), mammalian target 
of rapamycin (mTOR), and the pro-survival gene (Bcl-2) with small molecule 
inhibitors, TAK-165 (against HER2), NVP-BEZ235 (against PI3K and mTOR), and 
ABT-263 (against Bcl-2), singly or as cocktails, resulted in significant 
radiosensitisation of human breast cell lines with features similar to those of triple-
negative cancers. This radiosensitisation was seen at 2 and 6 Gy, indicating that a 
therapeutic benefit could be derived in conventional as well as stereotactic 
radiotherapy. A moderate to strong synergism was also demonstrated for NVP-
BEZ235/TAK-165 and NVP-BEZ235/ABT-263 cocktails. The strongest synergy was 
seen in the latter cocktail.  
 
In conclusion, inhibition of PI3K, mTOR and Bcl-2 could potentially be effective in the 
treatment of triple-negative breast cancer. The therapeutic benefit can be improved, if 
the target inhibition is followed by radiotherapy.  
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Opsomming 
 
 
Borskanker bly steeds die mees gediagnoseerde kanker en is die oorsaak van 32% 
van alle kankers en 15% van kankersterftes in vrouens. Pasiënte met drievoudige-
negatiewe-borskanker (TNBC) bedra een-vyfde van alle borskankerpasiënte. Dit is ‘n 
aggressiewe en heterogene siekte in vergelyking met ander tipes borskanker, en blyk 
weerstandig te wees teen geteikende en hormoonterapieë. 
 
Alhoewel kankerbehandeling vanaf ‘n ingrypende en hoogs toksiese terapie verander 
het na ‘n behandelingstrategie wat hoogs spesifiek met ’n laer toksisiteit is, word die 
sukses van kombinasie terapie met bestraling, teenliggaampies en middels weens 
inherente tumorweerstand ondermyn. Om hierdie belangrike kliniese uitdaging te 
oorbrug, is strategieë dus nodig om die onderliggende molekulêre meganismes van 
behandelingsweerstand te verstaan, en dan uit te skakel. Hierdie weerstand is die 
gevolg van die heterogeniteit in die verspreiding van potensiële antigene in ‘n 
tumorselpopulasie, wat veroorsaak dat nie al die selle geteiken word met ‘n toksiese 
dosis van die terapeutiese middel nie. 
 
Daar is aanduidings dat gebrekkige begrip en benadering van die proliferasiebane 
van drievoudige tumore dalk die fundamentele rede vir die waargenome 
behandelingsweerstand kan wees. Verder is daar ‘n gebrek aan geteikende 
modaliteitsterapieë wat doeltreffend is vir die behandeling van drievoudige 
borskanker, as gevolg van die lae uitdrukking van relevante teikens soos menslike 
epidermale groeifaktorreseptor-2 (HER2), progesteroonreseptor (PR) en 
estrogeenreseptor (ER). Nuwe behandelingstrategieë is dus nodig om die uitdagings 
met die behandeling van drievoudige-negatiewe-borskanker te bekamp en om 
resultate in pasiënte dus aansienlik te verbeter. ‘n Alternatiewe benadering sou kon 
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wees om ander selseinoordragentiteite as HER2, PR en ER te teiken en die tumore 
daardeur moontlik meer kwesbaar vir bestraling te maak. 
 
In hierdie studie het inhibisie van HER2, fosforinositied-3-kinase (PI3K), 
soogdierteiken vir rapamisien (mTOR), en die oorlewensgeen (Bcl-2) met klein 
molekuulinhibitore, TAK-165 (teen HER2), NVP-BEZ235 (teen PI3K en mTOR), en 
ABT-263 (teen Bcl-2), afsonderlik of in kombinasie, bewys dat betekenisvolle 
stralingsensitiwiteit in alternatiewe mensborssellyne, anders as die TNBC maar met 
dieselfde eienskappe, verkry kon word. Die stralingsensitiwiteit is merkbaar met 
beide 2 en 6 Gy, wat aandui dat beide gewone en stereotaktiese stralingsterapie ‘n 
terapeutiese voordeel inhou. ‘n Matige tot sterk sinergisme is ook aangetoon vir 
NVP-BEZ235/TAK-165- en NVP-BEZ235/ABT-263-kombinasies. Die sterkste 
sinergie kom in die laasgenoemde mengsel voor. 
 
Opsommend:  Chemoterapeutiese inhibisie van PI3K, mTOR en Bcl-2 kan potensieel 
effektief wees vir die behandeling van drievoudige-negatiewe-borskanker en die 
kliniese uitkoms kan verder verbeter word indien teikeninhibisie vóór bestraling kan 
plaasvind. 
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Chapter One: Introduction  
 
1.1. Breast Cancer: A Clinical Problem  
 
Breast cancer remains the most commonly diagnosed cancer in women. Statistics 
from the International Agency for Research on Cancer (IARC) indicate that there 
were 1 677 000 cases of breast cancer and 577 000 related deaths internationally in 
2012 (IARC, 2012). The most recent statistics show that in Africa approximately 29 
and 15 per 100 000 persons are diagnosed and die of breast cancer, respectively 
(Jemal et al., 2011). Furthermore, in economically developing countries like South 
Africa, this disease is the leading cause of cancer-related deaths in females (Jemal 
et al., 2011). The incidence and mortality rates of breast cancer in Southern Africa 
are higher than the continental average rates and are 38 and 19 per 100 000 
persons, respectively (Jemal et al., 2011).  
 
The different molecular subtypes of breast cancer exhibit significantly different levels 
of responses to treatment (van’t Veer et al., 2002; Yersal et al., 2012). These 
subtypes may be divided into several groups, namely: (1) human epidermal growth 
factor receptor 2 (HER2) positive; (2) oestrogen receptor (ER) and progesterone 
receptor (PR) positive; (3) ER and PR negative; and (4) triple-negative (HER2, ER 
and PR negative) (Sørlie et al., 2003). Cancers overexpressing the gene encoding 
HER2 constitute about 30% of invasive breast cancers (Slamon et al., 1987; Eccles 
et al., 2001; Iqbal et al., 2014; Perez et al., 2014). The humanised monoclonal 
antibody, trastuzumab, is approved by the United States Food and Drug 
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Administration (US FDA) for the treatment of HER2 positive cancers. However, 
trastuzumab only proves beneficial to breast cancers overexpressing HER2, while 
breast cancers lacking HER2 expression and low expressers of HER2 do not 
respond favourably to it. 
 
Oestrogen and progesterone positive breast cancers are reportedly the largest sub-
group and constitute 65-75% of the global breast cancer population (Carlson et al., 
2006). Seventy-five percent of patients with breast cancers expressing the oestrogen 
receptor receive endocrine therapy, but as many as 50% of this population fail to 
respond positively to this treatment as a result of acquired resistance (Clarke et al., 
2001; Baumgarten and Frasor, 2012).  
 
Triple-negative breast cancers (TNBC) constitute about one-fifth of all breast cancer 
patients (Foulkes et al., 2010). This subtype of breast cancer is known to occur more 
frequently in young Black and Hispanic women than in women of other racial or 
ethnic groups of comparable age (Millikan et al., 2008). TNBC is an aggressive and 
heterogeneous disease entity in comparison with other types of breast cancer, and 
therefore tends to be resistant to existing treatment regimens, such as targeted and 
hormone therapy (Darrel and Cleere, 2010).  
 
It is evident that certain sub-groups of breast cancer do not benefit from existing 
therapeutic regimens. To alleviate the breast cancer burden, there is an urgent need 
to develop novel and effective treatment approaches. Chemotherapeutic drugs have 
yielded a positive but limited treatment outcome in breast cancer patients with 
metastatic disease (Hurvitz et al., 2013). Radiotherapy, a common treatment 
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modality for certain types of breast cancer, has also proven beneficial for post-
operative local control, but radioresistance appears to lead to the development of 
recurrences (Jameel et al., 2004). Similarly, alternative treatment methods such as 
immunotherapy and the use of radiopharmaceuticals have limited success, partly 
due to their inability to effectively target all malignant cells with toxic amounts of a 
single therapeutic agent (Kvinnsland et al., 2001; Akudugu et al., 2011; Akudugu and 
Howell, 2012a, b).  
 
Also, cellular exposure to ionising radiation is known to activate the epidermal growth 
factor receptor, EGFR (Dittmann et al., 2005), and induce phosphoinositide 3-kinase 
(PI3K), serine-threonine protein kinase (Akt) and mammalian target of rapamycin 
(mTOR) activity downstream of the EGFR signalling pathway (Albert et al., 2006). 
This signalling promotes cell survival and can lead to treatment resistance. Targeting 
the HER2 pathway by inhibiting PI3K has also been shown to result in significant 
radiosensitisation (No et al., 2009). Of significance to targeted therapy, triple-
negative breast cancers, which are devoid of HER2 activity, tend to predominantly 
overexpress EGFR (Siziopikou et al., 2006). Therefore, developing therapeutic 
approaches that concurrently target EGFR family members and their downstream 
signalling components might significantly sensitise triple-negative breast cancer cells 
to radiotherapy and improve treatment outcome. 
 
Another plausible therapeutic approach for cancer would be to target signalling 
components that regulate the mechanism of apoptosis (programmed cell death) 
(Belka et al., 2004). Changes in this mechanism do not only cause the formation of 
cancer (Hellemans et al., 1995), but also leads to resistance to standard anticancer 
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therapies, namely, radiotherapy and cytotoxic agents (Krajewski et al., 1997). One of 
the suggested approaches to mitigate treatment resistance is to manipulate cellular 
expression of B-cell lymphoma-2 (Bcl-2) family members. Bcl-2 is an important anti-
apoptotic gene which interacts with its pro-apoptotic counterpart, Bax, to keep the 
balance between new cells and dying cells. Bcl-2 is usually over-expressed in 
human cancers (Hellemans et al., 1995; Olopade et al., 1997; Schneider et al., 1997; 
Pena et al., 1999; Trask et al., 2002). Increased levels of Bcl-2 are associated with 
resistance to chemotherapy and radiotherapy, leading to poor prognosis (Minn et al., 
1995; Reed et al., 1996; Simonian et al., 1997; Gallo et al., 1999). Therefore, 
inhibiting Bcl-2 presents a promising approach to overcoming resistance to 
conventional anticancer therapies. 
 
The challenges that are encountered due to acquired resistance to therapy and 
recurrences, therefore, warrant a continuous search for better treatment options for 
breast cancer.  
 
1.2. Rationale and Problem Statement 
  
Triple-negative breast cancers continue to be the most challenging subtype to treat, 
because it is a heterogeneous disease consisting of different subtypes, and cells 
present with different levels of receptor expression (Cleator et al., 2007; Stagg et al., 
2013; Jamdade et al., 2015; Lehmann et al., 2015). Inadequate expression of 
antigens that could potentially be therapeutic targets in triple-negative breast cancers 
may be responsible for the apparent resistance to existing treatment regimes, 
Stellenbosch University  https://scholar.sun.ac.za
5 
 
namely, targeted therapy, hormone therapy and radiotherapy. Furthermore, 
dissimilar to ER, PR and HER2 amplified breast cancers, the lack of high frequency 
oncogenic driver mutations in TNBC also contribute to limited molecular targeted 
treatments for this disease (Lehmann et al., 2015). To address these challenges, 
attempts have been made to better understand the molecular determinants of 
treatment resistance (Cleator et al., 2007; Weigelt et al., 2015). 
 
 This resistance can be attributed to the heterogeneity in the distribution of target 
antigen expression in a given cell population, which leads to the inability to 
effectively target all cells with toxic levels of therapeutic agents (Akudugu et al., 
2011, Akudugu and Howell, 2012a, b). There is also evidence to suggest that 
proliferative pathways of triple-negative tumours are still poorly understood, which 
could be the reason for the observed treatment resistance (Cleator et al., 2007; Ma 
et al., 2015). 
 
 What is lacking, however, is the ability to effectively target components of the cell 
survival pathways to achieve increased tumour response to therapy. This study 
sought to target HER2, PI3K, mTOR and Bcl-2 with specific inhibitors, in an attempt 
to: (1) radiosensitise human breast cancer cells with different expression levels of 
HER2, ER and PR; and (2) identify potential therapeutic targets for triple-negative 
breast cancer.  
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1.3. Hypothesis 
 
Targeting HER2, downstream signalling components of the EGFR family members, 
and Bcl-2 with specific inhibitors, singly or in combination, can significantly sensitise 
triple-negative breast cancer cells to ionising radiation. 
1.4. Aims and Objectives  
 
The aim of the study was to inhibit potential therapeutic targets in order to 
radiosensitise breast cancer cells that exhibit low expression levels of HER2, ER and 
PR.  For this, the following specific objectives were pursued: 
 To determine intrinsic cellular radiosensitivity of three human breast cell lines 
following exposure to 60Co -rays or X-rays. 
 To determine the cytotoxicity of specific inhibitors of HER2, PI3K, mTOR and 
Bcl-2 in each cell line. 
 To determine the radiomodulatory effects of the aforementioned inhibitors, 
singly or in combination, in each cell line. 
 To test whether flow cytometry could be used as a tool for rapid screening of 
potential target inhibitors as radiosensitisers. 
 
1.5. Significance of the Study  
Generally, optimisation of approaches for the treatment of metastatic breast cancers 
remains controversial. Over a decade ago, it was suggested that combination 
therapy had a place in the treatment of breast cancers (Miles et al., 2002). The 
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greatest concern with combination therapy is the toxicity of drugs used, as well as, 
the chosen combination that should meet three criteria;  
i. Each component should have single-agent activity with no antagonism. 
ii. There should be evidence of synergy between components. 
iii. The components should have no overlapping safety profiles. 
 
These three criteria are rarely met, and consequently many combination therapies 
have failed.  In this study, potential inhibitors were combined to radiosensitise breast 
cancer cells. The inhibitors TAK-285 and ABT-263 (Aertgeerts et al., 2011; Bajwa et 
al., 2012) have single agent activity and the NVP-BEZ235 inhibitor has dual agent 
activity (Maira et al., 2008). The study reported here demonstrates that using a 
cocktail of NVP-BEZ235 in combination with TAK-165 or ABT-263 can significantly 
radiosensitise breast cell lines, based on clonogenic cell survival.  These findings 
suggest that the cocktail combinations may not only have the potential for effectively 
targeting triple-negative breast cancer cells, but that there may be no antagonism 
between inhibitors. A second advantage of using the cocktail combinations is that the 
combination indices (CI) for the NVP-BEZ235/TAK-165 and NVP-BEZ235/ABT-263 
cocktails for all cell lines ranged between 0.20 and 0.74,  indicating synergism for 
each inhibitor combination (Chou 2006). 
 
Although the inhibitors used here, and radiation, have overlapping safety profiles 
which includes nausea, diarrhoea, vomiting and fatigue, clinical studies report that 
the side effects of NVP-BEZ235, ABT-263 and TAK-165 are generally well tolerated 
(Sridhar et al., 2003; Gandhi et al., 2011; Martini et al., 2013). Other more severe 
side effects, like thrombocytopenia, from ABT-236 administration are dose-
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dependent. Systemic toxicity is also a significant concern in the clinic and lower drug 
doses are desirable. Combination indices estimated for each cocktail in this study 
show an improvement in synergism when the concentration of the common 
component NVP-BEZ235 was decreased, suggesting that radiosensitisation may 
persist even at low inhibitor concentrations and resulting toxicity may be minimal.  
   
In conclusion, this study demonstrates the following: 
 Inhibition of HER2, PI3K, mTOR and Bcl-2 in breast cell lines with diminished 
expression of HER2, ER and PR with specific inhibitors is cytotoxic. Use of 
such inhibitors could potentially have a therapeutic benefit for triple-negative 
breast cancer.  
 Pre-treatment of apparently normal and malignant human breast cells with 
specific inhibitors of HER2, PI3K, mTOR and Bcl-2, singly or in combination, 
sensitises them to low and high doses of ionising radiation. Concomitant 
treatment of breast cancers with low expression of HER2, ER and PR with 
such inhibitors and radiotherapy may improve prognosis in triple-negative 
breast cancer patients. 
  
Findings of this study may also make a significant contribution to the design of novel 
treatment approaches for breast cancer in particular, and cancer as a whole. 
 
1.6. Delineations  
 
This study used inhibitors of HER2, PI3K, mTOR and Bcl-2 to radiosensitise three 
human breast cell lines (MCF-7, MDA-MB-231 and MCF-12A) which are low 
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expressers of HER2, and cover a wide range of ER, PR, EGFR, PI3K and Bcl-2 
expression. The expression levels of the selected targets in the three cell lines were 
not determined prior to inhibition, as these have been reported in several studies 
(Horwitz et al., 1975; Kandouz et al., 1996; Rusnak et al., 2001; Konecny et al., 
2006; Vasudevan et al., 2009; Subik et al., 2010; Carlson et al., 2010; Brosseau et 
al., 2012).  
 
The research variables determined in this study are intrinsic cellular radiosensitivity, 
cytotoxicity of specific inhibitors of HER2, PI3K, mTOR and Bcl-2, radiomodulatory 
effects of inhibitors given either singly or in combination, and treatment-induced 
expression of the pro-apoptotic gene, Bax.   
 
Clonogenic cell survival following irradiation was determined to enable comparison of 
intrinsic cellular radiosensitivity of the three cell lines. Cytotoxicity of inhibitors was 
determined, using the colony forming assay to extract the equivalent concentration 
for 50% cell killing (EC50) for each cell line. From the cytotoxicity data, combination 
indices were determined and used to decipher the modes by which inhibitors 
interacted with each other when combined in a cocktail. The EC50-values were used 
to guide subsequent radiomodulatory experiments, in which radiation modifying 
factors were derived to determine how a particular inhibitor or inhibitor cocktail 
impacted cellular radiosensitivity. Flow cytometry was used to test if a rapid 
measurement of treatment-induced Bax expression can potentially replace the 
expensive and slow colony forming assay as a tool for high throughput screening of 
candidate target inhibitors.  
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These research variables were deemed sufficient to prove the research hypothesis. 
Some of the data presented have been published (Hamunyela et al., 2015, copy 
attached).  
 
1.7. Limitations 
 
 This work only used three human breast cell lines as they were the only ones 
available at the time.  
 The 60Co -irradiator initially used for the study was decommissioned, and cell 
irradiation was continued with a Faxitron MultiRad 160 X-irradiator.  
 The TAK-165 inhibitor was used as a generic inhibitor of HER2 as the approved 
trastuzumab that is used routinely for therapy is expensive and not readily 
accessible for basic research. 
 Only one cell line (MDA-MB-231) was used to test the feasibility of using flow 
cytometry as a rapid high throughput tool for evaluating candidate target 
inhibitors for therapeutic benefit due to financial constraints.  
 Inhibitors were not validated at a molecular level using western blotting, due 
to technical difficulties arising from a number of attempts. 
 The radiomodulatory effects of the inhibitors were not assessed for the full cell 
survival-dose response curves due the prohibitive cost of inhibitors. 
 A TAK-165 and ABT-263 combination was not evaluated due to financial 
constraints. 
 Assessment of additional time points for irradiation after inhibitor treatment 
would also be of significant value in understanding the mode of action of 
combination therapy. This was not feasible for reasons of cost.  
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1.8. Background Literature 
 
1.8.1. Types of Breast Cancer  
 
An approach to identify breast tumour subtypes was first described by Sørlie et al. 
who used molecular characteristics to group tumours into various biological subtypes 
(Sørlie et al., 2001). The greatest difference between the subtypes was seen in 
hormone receptor positive and hormone receptor negative tumours. The hormone 
receptor positive tumours were clustered in two groups which had expression 
characteristics seen in luminal epithelial mammary cells. The hormone receptor 
negative tumours were clustered into three molecular types: tumours that had 
characteristic gene expression seen in basal or myoepithelial mammary cells, 
tumours with an overexpression of HER2 gene, and tumours that presented with 
expression characteristics related to normal mammary cells (Sørlie et al., 2001).  
In all, breast cancers can be classified into seven common subtypes, namely, 
claudin-low, basal-like, HER2 positive, normal-like breast tumour, triple-negative, 
luminal A, and luminal B; as well as a luminal C intrinsic subtype which is discerned 
from the luminal A and B by a unique set of genes with unknown function, a common 
characteristic they have with the basal-like and HER2 positive tumours (Perou et al., 
2000; Sørlie et al., 2001; Kittaneh et al., 2013). Other newer classifications of 
“luminal-like” subtypes of breast tumours provide useful information on breast cancer 
biology, but have not yet been applied in clinical practice.  
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1.8.2. Clinically Common Breast Cancer Subtypes  
 
The most common clinically used molecular characteristics of breast cancer 
subtypes are summarised in Table 1.1.  
 
Table 1.1: Gene expression profiles of subtypes of breast cancer. 
Classification Immunoprofile CK5/6 EGFR status Frequency (%) 
Claudin-low  ER-, PR-, HER2- EGFR+/- 12–14 
Luminal A ER+, PR+/-, HER2- EGFR - 50–60 
Luminal B ER+, PR+/-, HER2+ EGFR - 10–20 
HER2 enriched ER-, PR-, HER2+ EGFR+/- 10–15 
Normal breast type ER+/-,  HER2- EGFR+ 5–10 
Basal ER-, PR-, HER2- EGFR+ 10–20 
Triple-negative  ER-, PR-, HER2- EGFR+ 20–25 
ER: oestrogen receptor; PR: progesterone receptor; CK5/6 Cytokeratin5/6; HER2: human epidermal 
growth factor receptor 2; -: negative; +: positive; +/- occasionally positive; -/+: rarely positive.  
(Holliday and Speirs, 2011; Eroles et al., 2012; Weigelt et al., 2010) 
 
 
The luminal-like subtype derives its name from similarities in the expression profile of 
the normal luminal breast epithelium lining. Luminal A is the most common type of 
breast cancer. This subtype expresses ER regulated genes and under-expresses 
HER2 and genes involved in proliferation (Eroles et al., 2012; Kittaneh et al., 2013). 
Luminal B is characterised by a low ER expression and a moderate HER2 
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expression, while possessing high expression levels of genes regulating cell 
proliferation (Kittaneh et al., 2013). 
 
HER2 positive breast cancers are characterised by their expression of the HER2/neu 
gene. These breast cancers mostly present with a low expression of luminal gene 
clusters (namely, the luminal cytokeratins: CKs, CK7, CK8, CK18 and CK19). As 
illustrated in Table 1.1, HER2 enriched tumours are ER and PR negative (Eroles et 
al., 2012; Kittaneh et al., 2013). 
 
The normal-like breast cancer gene expression is identified by the overexpression of 
the basal epithelial genes and a lower expression of luminal epithelial genes (Perou 
et al., 2000). The basal-like (BBC) breast cancers are one of the subtypes of breast 
cancers which derives its name from its expression of genes usually present in the 
normal myoepithelial cells. Basal-like cancers are commonly identified by their 
immunohistochemical staining for the expression of cytokeratin 5/6 (CK5/6). Most 
basal-like cancers do not express ER, PR or HER2; however, a small number do  
and thus overlap with the triple-negative subtype (Jimenez et al., 2001; Jones et al., 
2001; Nielsen et al., 2004; Eroles et al., 2012; Kittaneh et al., 2013).  
 
Triple-negative breast cancers (TNBC) are defined as cancers that do not express 
hormone receptors (ER and PR) nor overexpress HER2. The features of this group 
are similar to those of the basal-type (Table 1.1). Consequently, pioneering gene 
expression and cellular pathway studies that led to development of the different 
subtypes of breast cancer did not distinguish between the two subtypes (Morris and 
Carey, 2007; Rakha et al., 2009). Nonetheless, the subtypes are distinguishable in 
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that while triple-negative cancers do not form a homogeneous cluster in accordance 
to the relationship between gene expression profiles and response to therapy, their 
basal-like counterparts do (Bertucci et al., 2008; Rakha et al., 2009). Such 
heterogeneity in gene expression, as exhibited by triple-negative cancers, can 
further exacerbate the current treatment challenges. Triple-negative tumours also 
overexpress epidermal growth factor receptor (EGFR) which is responsible for 
activating signalling pathways involved in cell survival and carcinogenesis (Cunliffe 
et al., 2003; Krause and Van Etten., 2005; Pao et al., 2005; Siziopikou et al., 2006). 
Treatment resistance in TNBC may, therefore, be attributable to EGFR 
overexpression.  
 
Triple-negative breast cancers also have features of other subtypes of breast 
cancers. These include the claudin-low breast cancers which do not express normal 
differentiation markers, hormone receptors, and HER2 (Kittaneh et al., 2013). Also, 
the triple-negative subtype has features similar to those of the normal breast cancer 
subtype (Sørlie et al., 2001). Put together, triple-negative breast cancer is the most 
heterogeneous and complex subtype, and therefore poses a significant treatment 
challenge. The interrelationships of the various breast cancer subtypes are depicted 
in the schematic Figure 1.1 below. 
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Figure 1.1: Different breast cancer types and their features.  
 
1.8.3. PI3K/Akt/mTOR Pathways in Malignant Transformation 
 
Cell-to-cell communication and how cells interpret such signals into metabolic, 
survival, proliferative, and death responses has become a central study area (Dent 
et al., 2003). Domains of the EGFR protein signalling induce receptor 
homodimerisation or heterodimerisation with members of the ErbB family, namely, 
HER1, HER2, HER3, and HER4 (Yarden and Sliwkowski, 2001). Dimerisation of 
ErbB family members further leads to activation of the tyrosine kinase domain, 
autophosphorylation, and thus activation of various downstream pathways, such as, 
the PI3K/Akt/mTOR pathway and the Ras/Raf/MAPK pathway (Valabrega et al., 
2007; Bender and Nahta, 2008). EGFR signalling either promotes cell proliferation 
via the Ras-MAPK pathway or inhibits apoptosis (leading to cell survival) through the 
Akt/mTOR pathway (Yarden and Sliwkowski, 2001). Identification of resistance 
mechanisms in the PI3K/Akt/mTOR pathway can provide information that may aid in 
developing new approaches which will lead to improved breast cancer management. 
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This pathway is the most commonly activated pathway in human breast cancers, and 
thus presents itself as a potential target for therapy (Liu et al., 2009). 
 
Figure 1.2 shows possible treatment targets in breast cancers. Potential targets 
include the EGFR family members and components of the MAPK and 
PI3K/Akt/mTOR pathways.  
    
Figure 1.2: Potential therapeutic targets (red ovals) for breast cancer (Cleator et al., 2007; Martin et 
al., 2013).  
 
The following is a brief summary of the modes by which the targets evaluated in the 
study (HER2, the components of the PI3K/Akt/mTOR pathway, and Bcl-2) are 
involved in treatment resistance: 
A B 
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1.8.4. HER2  
 
Trastuzumab has been shown to have no clinical benefit in breast cancers 
expressing normal or low levels of the HER2 protein (p185HER2), indicating that a 
certain level of gene amplification is necessary for trastuzumab to be effective 
(Burstein, 2005; Vicario et al., 2015). In general, a cell population would exhibit a 
wide variation in the distribution of antigens of interest with sub-populations of cells 
expressing low, moderate, or high levels of the antigens. Another challenge in this 
treatment modality is that some HER2 positive cancers express a constitutively 
active truncated form of the protein (p95HER2). This truncated HER2 does not 
present with the extracellular domain necessary for trastuzumab binding, thereby, 
leading to poor treatment response (Pohlmann et al., 2009). This significance of 
p95HER2 in apparent resistance to trastuzumab therapy cannot be overemphasized. 
As much as 60% of HER2 positive tumours are known to express p95HER2 
(Christianson et al., 1998; Molina et al., 2002; Scaltriti et al., 2015). Lapatinib, 
another drug approved by the US FDA, appears to be more potent for treating 
cancers exhibiting high levels of p95HER2 (Scaltriti et al., 2007). Failure to 
accurately identify the variant of HER2 that is overexpressed (i.e. p185HER2 or 
p95HER2) can lead to ineffective targeting and treatment resistance. Heterogeneity 
in the distribution of p185HER2 or p95HER2 in a tumour cell population can result in 
the inability to effectively target all cells with toxic levels of trastuzumab or lapatinib, 
respectively.  
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1.8.5. PI3K and mTOR  
 
The phosphatase and tensin homolog (PTEN) is a tumour suppressor gene, which 
inhibits PI3K. Loss of functionality of PTEN via self-mutation or transcriptional 
regulation has been noted in 50% of breast cancers (Pandolfi, 2004). This loss of 
PTEN activity results in constitutive up-regulation of PI3K/Akt/mTOR phosphorylation 
and signalling which, in turn, prevents cell death, making tumours resistant to 
conventional treatment (Pohlmann et al., 2009). Also, PI3K in its mutated form has 
been implicated in resistance to therapy (Eichhorn et al., 2008). Mutations in PI3K 
have been shown to significantly activate the PI3K/Akt/mTOR pathway, leading to 
enhanced cell survival following cancer therapy (Jimenez et al., 1998; Philp et al., 
2001). 
  
1.8.6. Bcl-2 
 
Stimuli, such as, DNA damage, hypoxia, high concentrations of cytosolic Ca2
+, and 
severe oxidative stress can trigger apoptotic cell death via an intrinsic mitochondrial 
pathway. This pathway is initiated when the pro-apoptotic Bcl-2 family member, Bax, 
translocates from the cytoplasm onto the mitochondrial membrane causing the 
mitochondrion to become very permeable resulting in the release of the pro-
apoptotic molecule (Cytochrome C) into the cytoplasm (Danial and Korsmeyer, 
2004). The release of Cytochrome C then results in an irreversible cascade of pro-
apoptotic processes that are mediated by a panel of caspases, namely, caspases 9, 
3, 6 and 7. The anti-apoptotic protein, Bcl-2, blocks this pathway by inhibiting the 
translocation of Bax onto the outer mitochondrial membrane. An overexpression of 
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Bcl-2 in a tumour can, therefore, be expected to result in an increased evasion of 
apoptosis when cells are exposed to therapeutic agents, thereby leading to 
treatment resistance and poor prognosis (Minn et al., 1995; Reed et al., 1996; 
Simonian et al., 1997; Gallo et al., 1999; Ong et al., 2001).  
 
1.8.7. Treatment for Breast Cancer   
 
Breast cancer treatment choices are generally based on its tumour-node-metastasis 
status. Other important factors to consider are lymphovascular spread, histologic 
grade, hormone receptor status (ER and PR), HER2 expression status, the presence 
of other pathologies, menopausal state, and age. This section summarises the 
recommended treatment regimens for different types of breast cancers according to 
their stage, histology and the expression of ER, PR and HER2. Furthermore, this 
section focuses on the treatment options relevant to this research study. Here, 
radiation absorbed doses of 2 and 6 Gy are used. The relevance of using these 
doses with reference to clinical fractionation radiotherapy regimes is also highlighted. 
Table 1.2 summarises the treatment options for the different stages of breast 
cancers (Maughan et al., 2010). 
  
Stellenbosch University  https://scholar.sun.ac.za
20 
 
Table 1.2: Treatment options for breast cancer by stage. 
 Breast Cancer Stage  Therapy*  
Stage 0: in situ 
 No treatment or consider 
prophylaxis with tamoxifen;  
 Breast-conserving surgery 
(mastectomy and radiotherapy are 
considered if extensive or 
multifocal) 
Stage I and II: Early stage invasive Breast-conserving surgery and 
radiotherapy 
Stage III: Locally advanced  Chemotherapy followed by breast- 
conserving therapy or mastectomy and 
radiotherapy 
Stage IV: Metastatic  Address patient’s treatment goals; 
radiation; bisphosphate for pain  
*Adapted from Maughan et al. (Maughan et al., 2010). 
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Table 1.3 summarises the treatment options for the different subtypes of breast 
cancer according to their expression of the biomarkers ER, PR and HER2 
(Goldhirsch et al., 2011). 
 
 
Table 1.3: Treatment options for breast cancer subtypes.  
Breast Cancer Subtype  Recommended therapy* 
Luminal A Endocrine therapy. 
Luminal B Endocrine therapy, cytotoxic therapy and 
anti-HER2 therapy. 
HER2 enriched  Cytotoxic therapy and anti-HER2 
therapy. 
Basal-like  Cytotoxic therapy.  
Triple-Negative  Cytotoxic therapy. 
*Adapted from Goldhirsch et al. (Goldhirsch et al., 2011). 
 
1.8.8. Treatment Options  
 
1.8.8.1. Radiation Therapy 
 
The use of radiation has been appreciated in the clinical setting as a cancer 
treatment option since its discovery over a century ago. Sixty percent of solid 
tumours are treated with radiation, and this emphasises the importance of this 
therapeutic regimen with 15% of cancer patients receiving radiation alone and 45% 
treated with a combination of radiation and other modalities (Prasanna et al., 2014).  
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Although ionising radiation damages the deoxyribonucleic acid (DNA) of normal and 
malignant cells and can prevent cells from dividing (Jackson and Bartek, 2009) or 
may induce cell death (Baskar et al., 2012), the rationale for radiation therapy is to 
deliver high doses to the cancerous cells while keeping doses to healthy cells at a 
minimum. A differential response to radiotherapy between normal and tumour cells 
can be harnessed, as tumour cells are highly proliferative and may be more 
radiosensitive than their normal counterparts.     
In the clinical setting, radiation may be given alone with the intention to completely 
cure a cancer or simply for palliative purposes. Often, radiotherapy may be used to 
either shrink a tumour prior to surgery (neoadjuvant therapy) or to destroy residual 
disease after surgery (adjuvant therapy). Different types of cancers have different 
levels of radiosensitivity. While some early cancers (e.g. cancers of the skin, 
prostate, lung, cervix, and head-and-neck) are curable with radiation alone, others 
(e.g. cancers of the breast, rectum, anus, bladder, and endometrium; and locally 
advanced head-and-neck cancers, lymphomas, central nervous system soft tissue 
sarcomas, and paediatric tumours) may be cured with radiation in combination with 
molecular targeted therapies (Baskar et al., 2012). 
 
In general, radiotherapy has been beneficial in the treatment of breast cancer, 
especially for palliative treatment. Depending on the stage of the disease, radiation 
therapy may reduce recurrences and improve patient survival. Despite the positive 
outcomes seen in breast cancer radiotherapy, multimodality treatment approaches 
involving the combined use of radiotherapy, chemotherapy, hormonal therapy, and 
molecular targeted therapy are highly desirable if the disease is to be completely 
eradicated (Eniu et al., 2006). There are numerous clinical trials on the use of 
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combinations of small molecule inhibitors and chemotherapy drugs that demonstrate 
acceptable safety profiles and significant therapeutic benefit for breast cancer 
management (Miller et al., 2005; Burstein et al., 2008; Liljegren et al., 2009; Brufsky 
et al., 2011; Robert et al., 2011; Gianni et al., 2012; Hurvitz et al., 2013; Pritchard et 
al., 2013; Luu et al., 2014; Roviello et al., 2016).  However, there appears to be a 
general paucity of similar studies involving the combination of these inhibitors with 
radiotherapy (Jacob et al., 2014; Murphy et al., 2015). This is likely due to the fact 
that the concept of targeted therapy is relatively new, and studies combining small 
molecule inhibitors and radiotherapy are predominantly still in the preclinical phase 
(Sambade et al., 2010; Li et al., 2012).  
  
Typically, radiotherapy may be given as many fractions at 2 Gy per fraction 
(conventional radiotherapy) or as fewer fractions at 3-20 Gy per fraction 
(hypofractionated radiotherapy) (Prasanna et al., 2014). The main advantages of 
hypofractionated radiotherapy are reduced treatment time and cost. The risk of 
encountering unintended treatment gaps is also significantly reduced relative to that 
for conventional radiotherapy. Although there are some concerns regarding normal 
tissue toxicity from the high fractional doses employed in hypofractionated 
radiotherapy, improvements in radiation therapy planning and dose delivery have 
adequately allayed these fears. 
 
Besides causing cell death, DNA damage induced by ionising radiation can cause 
cells to express a variety of proteins that are crucial for damage repair, cell survival, 
and proliferation. For instance, radiation-induced damage activates the ataxia 
telangiectasia mutated (ATM) or ATM- and RAD3-related proteins, which 
Stellenbosch University  https://scholar.sun.ac.za
24 
 
subsequently induce growth factor receptors to promote proliferation. Irradiation of 
cancer cells can also increase expression of transforming growth factor α (TGFα) 
which activates EGFR (Baselga et al., 1996; Levenson et al., 1998). Increased 
proliferation rates in cancers and poor prognosis have been correlated with elevated 
expression of EGFR (Putz et al., 1999). Clinically relevant radiation doses of 1-2 Gy 
are known to activate HER2 and its downstream effectors PI3K, Akt and mTOR 
(Contessa et al., 2002; Dent et al., 2003; Escriva et al., 2008). The same is true for 
cellular exposure to much higher doses of radiation (Liang et al., 2003). Cell 
exposure to ionising radiation also induces PTEN and PI3K activity (Contessa et al., 
2002; Escriva et al., 2008). The EGFR, PI3K/Akt/mTOR and Ras/Raf/mitogen 
activated protein kinase (MAPK) pathways have been shown to mediate cellular 
radiosensitivity (Valerie et al., 2007). Targeting these molecular signalling 
components could lend itself as an effective approach for breast cancer treatment.  
 
1.8.8.2. Targeted Therapy  
 
The rationale for targeted therapy is to capitalise on proteins that are differentially 
overexpressed in cancer cells, relative to their normal counterparts. These proteins 
usually play a key role in cancer cell proliferation and survival. Interfering with the 
activity of these protein targets can, therefore, have a specifically adverse effect on 
cancer cell growth and survival. Traditional chemotherapy targets and kills both 
cancerous cells and rapidly dividing cells of normal tissues (e.g. hair, bone marrow, 
and gastrointestinal epithelium). In contrast, targeted therapies are aimed at 
molecular targets that are associated with carcinogenesis and tend to block tumour 
proliferation (Gerber, 2008).   
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Agents used in this therapeutic approach are usually present as small molecules for 
targets within cells or as relatively large molecules for targets outside the cells, or on 
the cell membrane (Gerber, 2008). These are usually only effective if a tumour 
presents with the specific target of interest. The most common cancer proliferation 
pathways targeted in breast cancer are those of the epidermal growth factor receptor 
(EGFR), vascular endothelial growth factor receptor (VEGF), and human epidermal 
growth factor receptor (HER2/neu). These pathways can be blocked by neutralising 
molecules that bind to receptor sites on cells to prevent dimerisation, stopping 
receptor signalling within the cell, or interfering with signalling proteins downstream 
of the pathways (Gerber, 2008). 
 
The use of targeted therapy has changed the outcomes of some cancers in the 
clinical setting. The tyrosine-kinase inhibitor, imatinib, has had great effects on 
chronic myeloid leukaemia (Thiele et al., 2004). The monoclonal antibody against B-
cell surface protein CD20, rituximab, and another tyrosine-kinase inhibitor, Sunitinib, 
have improved the outcome of non-Hodgkin’s lymphoma and renal cell carcinoma 
(Bharthuar et al., 2009;  Dotan et al., 2010; Vázquez-Alonso et al., 2012). Also, the 
humanised monoclonal antibody, trastuzumab, has revolutionised the treatment of 
HER2 positive cancers (Romond et al., 2005). Combining chemotherapy with 
targeted therapy has also proven beneficial in some instances. The survival rate has 
been found to increase from 17% to 24% when patients with advanced pancreatic 
cancer are treated with chemotherapy in combination with the EGFR inhibitor, 
erlotinib (Moore et al., 2007). In addition to improving treatment prognosis, targeted 
therapy lends itself as a tolerable therapeutic alternative for patients scheduled for 
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anticancer therapy. For example, in elderly patients with small-cell lung carcinoma 
and non-Hodgkin’s lymphoma who present with other medical conditions that limit 
the use of traditional chemotherapy, erlotinib and rituximab are less toxic and more 
tolerated.  
 
Monoclonal antibodies have led to truly tailored therapy. Trastuzumab, a monoclonal 
antibody related to EGFR that interferes with the HER2 receptor, has been used with 
significant success in the treatment of breast cancer. This antibody was formulated 
after overexpression of human epidermal growth factor receptor 2 (HER2) was 
identified both as an aggressive disease marker and a treatment target (Burstein, 
2005). Cancers overexpressing the gene encoding HER2 constitute 30% of invasive 
breast cancers (Slamon et al., 1987; Eccles et al., 2001). Biochemically, trastuzumab 
binds to the extracellular juxtamembrane domain of the full-length HER2. This 
binding causes a downregulation of HER2 expression, changes downstream 
signalling and regulatory pathways in the cancer cell cycle, inhibits the formation of 
new vasculature and leads to cell death (Burstein, 2005). Trastuzumab is, therefore, 
ineffective in breast cancers that do not overexpress HER2 (Bast et al., 2001; 
Romond et al., 2005) or those overexpressing the constitutively active truncated form 
of the protein which does not present with the extracellular domain necessary for 
trastuzumab binding (Pohlmann et al., 2009). In the latter cases, lapatinib may be 
used. The involvement of HER2 in many cellular response pathways, as mentioned, 
makes it an ideal target for effective breast cancer treatment.  
 
Compared to monoclonal antibodies, small molecule inhibitors are less specific and 
have the ability to bind to multiple targets. These inhibitors tend to compete with 
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adenosine triphosphate (ATP) to prevent phosphorylation of tyrosine kinases like 
EGFR, HER2 and VEGF, and subsequent downstream signalling events (Aertgeerts 
et al., 2011). For instance, lapatinib is a small molecule that inhibits both EGFR and 
HER2 (Moulder et al., 2001; Tural et al., 2014). 
 
1.8.8.3. Radiosensitisation by Targeted Therapy  
 
There are many cell signalling cascades that govern the response of cells to different 
stimuli. The PI3K/Akt/mTOR pathway has been demonstrated to have a clear role in 
cellular response to ionising radiation (Kirshner et al., 2006). Activation of this 
pathway leads to increased uptake of glucose for metabolism, suppression of 
apoptosis, and enhanced cell survival (Schlessinger, 2000; LoPiccolo et al., 2008).  
Some monoclonal antibodies and small molecule inhibitors against components of 
this pathway are now in use as modulators of radiation response in the clinic. The 
EGFR-specific antibody, cetuximab, when used in combination with radiotherapy, 
has been most beneficial in increasing locoregional control and overall survival in 
patients with head-and-neck cancer (Bonner et al., 2006; 2010). Small molecule 
inhibitors against proteins of the PI3K/Akt/mTOR pathway and receptor tyrosine 
kinase inhibitors are also able to interfere with EGFR signalling and lead to tumour 
radiosensitisation (Bianco et al., 2002; Dutta and Maity, 2007; Feng et al., 2007). 
 
1.8.8.4. Treatment Options for Triple-Negative Breast Cancer 
 
Although a subset of triple-negative breast cancers respond to cytotoxic 
chemotherapy, the long-term prognosis of the treatment modality varies markedly 
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(Haffty et al., 2006; Kassam et al., 2009; Foulkes et al., 2010). In the neo-adjuvant 
setting, patients with triple-negative breast cancer who do not respond to 
chemotherapy before surgery relapse within two years and have a poor overall 
survival of 3 years (Dent et al., 2007; Morris and Carey, 2007; Millikan et al., 2008).  
 
Triple-negative breast cancers are the most difficult to treat, and there are limited or 
no specific treatment options as these cancers are often devoid of significant 
expression of targets such as HER2, PR, and ER.  A few systemic treatment 
approaches that are currently used for the management of triple-negative cancer are 
listed in Table 1.4.  
 
Table 1.4: Potential systemic target-specific treatment protocols for triple-negative breast cancer. 
Treatment Target* 
Cytotoxic chemotherapy with agents that cause inter-strand 
breaks (e.g. platinum-based drugs)  
DNA 
PARP1 inhibitors PARP1 
Antibodies (e.g. Cetuximab) and small molecule inhibitors 
(e.g. Gefitinib) 
EGFR 
c-KIT tyrosine kinase inhibitors (e.g. Imatinib) c-KIT 
Multi-kinase inhibitors (e.g. Lapatinib and Pertuzumab) EGFR/ERBB2 
Second-messenger inhibitors Ras, Raf, MEK, 
mTOR, Src, Hsp90 
*Adapted from Cleator et al. (Cleator et al., 2007). 
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Recurrent and metastatic triple-negative breast cancers tend to be very aggressive 
with a high proliferation index, invading the visceral and central nervous system 
(Liedtke et al., 2008; Smid et al., 2008). In such scenarios, the mean survival may be 
shortened to just 12 months.  
 
Although there is evidence to suggest a benefit for adjuvant radiotherapy in the 
management of triple-negative breast cancer (Abdulkarim et al., 2011), it has been 
asserted that this regimen does not significantly enhance locoregional control and 
reduce disease progression (Haffty et al., 2006; Panoff et al., 2011; Dragun et al., 
2011). Identification and validation of specific targets for triple-negative breast cancer 
therapy are highly desirable in the clinic. To this end, intensifying the search for 
effective small molecule inhibitors targeting proliferative and survival pathways, as 
alluded to in Table 1.4, and evaluating how these inhibitors may modulate the effects 
of radiotherapy, is warranted.  
 
The unique features of the pro-survival PI3K/Akt/mTOR pathway have made its 
inhibition an attractive option for the development of new strategies for cancer 
treatment. A new generation of inhibitors that target the PI3K pathways are 
emerging, and these inhibitors are overcoming initial problems of poor target 
selectivity, undesired pharmacokinetics, and excessive toxicity. A few of these 
agents have entered early phase clinical trials. Inhibitors of HER2 and EGFR, such 
as TAK-165, are long known to radiosensitise breast cancer cells (Liang et al., 
2003). TAK-165 has also been shown to exhibit significant anti-tumour effects in 
xenograft models of kidney, bladder and prostate cancer (Nagasawa et al., 2006). 
The dual inhibitor of PI3K and mTOR, NVP-BEZ235, has been shown to have anti-
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proliferative and cytotoxic activity in a panel of 21 cell lines of different origins (Serra 
et al., 2008). Radiosensitisation of xenografts established from the breast cancer cell 
lines, MDA-MB-231 and MCF-7, by NVP-BEZ235 has been demonstrated under 
normoxic and hypoxic conditions (Kuger et al., 2014). NVP-BEZ235 has also been 
shown to attenuate DNA double-strand-break repair in glioblastoma cells, resulting in 
marked radiosensitisation (Mukherjee et al., 2012). Inhibition of Bcl-2 alone or in 
conjunction with mTOR, in in vitro systems or xenograft models, has been shown to 
radiosensitise cells originating from non-small-cell lung carcinoma and head-and-
neck cancer (Tse et al., 2008; Kim et al., 2009; Zerp et al., 2015). Collectively, these 
reports suggest that informed targeting of components of the PI3K/Akt/mTOR 
pathway and Bcl-2 might render many cancers more susceptible to radiotherapy.  
 
In this study, it is anticipated that targeting HER2, PI3K, mTOR and Bcl-2 with 
specific inhibitors might preferentially sensitise cancer cells that are either devoid of 
or are low expressers of HER2, oestrogen receptor (ER) and progesterone receptor 
(PR) to radiotherapy. NVP-BEZ235 inhibits PI3K and mTOR leading to the induction 
of apoptosis in breast tumour cell lines (Kuger et al., 2014). HER2 inhibitor Herceptin 
has also been shown to be cytotoxic in breast cell lines (Liang et al., 2003). Bcl2/Bcl-
XL inhibitors proved to have radiosensitising effects in other cancers (Loriot et al., 
2014). Despite these promising findings, normal toxicity is of significant concern as 
normal cells also express some of the targets of interest. However, sensitisation to 
radiation treatment by some inhibitors appears to be specific for cancer cells.  
Inhibition of PI3K and mTOR with NVP-BEZ235 has also been shown to 
radiosensitise prostate cancer cells, but acts as a radioprotector in normal prostate 
cells and mouse gut (Potiron et al., 2013; Maleka et al., 2015). Testing these HER2, 
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PI3K, mTOR and Bcl-2 inhibitors on a panel of malignant and normal cell lines may 
assist in identifying those with higher levels of specificity for malignants, and could 
aid in inhibitor selection for improved therapeutic benefit. This should provide 
potential therapeutic approaches for triple-negative breast cancer.   
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Chapter Two: Research Methodology 
 
2.1. Chemicals, Specific Inhibitors, Antibodies, and Culture Medium  
 
2.1.1. Reagents for Colony Forming Assay 
 
2.1.1.1. Fixative  
The fixative for the clonogenic cell survival assay consisted of a mixture of glacial 
acetic acid, methanol and deionised water in the ratio of 1:1:8 (v/v/v).  
 
2.1.1.2. Staining Solution  
Colonies were stained with 0.01% Amido black (Naphthol Blue Black) in fixative. 
 
2.1.2. Reagents for Flow Cytometry  
 
2.1.2.1. Stock Buffers   
2.1.2.1.1. 10 permeabilisation buffer (eBioscience, California, USA; cat #: 00-8333). 
2.1.2.1.2. 1 BD Cytofix (eBioscience, California, USA; cat #: 00-8222). 
 
2.1.2.2. Working Buffers   
2.1.2.2.1. Permeabilisation buffer:  10 permeabilisation buffer (eBioscience, 
California, USA; cat #: 00-8333) diluted 1:10 in distilled water. 
2.1.2.2.2. Fixation buffer: 1 BD Cytofix (eBioscience, California, USA; cat #: 00-
8222). 
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2.1.2.3. Fluorochrome-Conjugated Antibody   
2.1.2.3.1. Mouse anti-human phycoerythrin-conjugated antibody, Bax antibody 
(6D149) PE (Santa Cruz Biotechnology, Texas, USA; cat. #: sc-70405).   
 
2.1.3. Specific Inhibitors 
  
2.1.3.1. NVP-BEZ235  
As illustrated in Figure 2.1, NVP-BEZ235 (C30H23N5O; Mw = 469.55; Santa Cruz 
Biotechnology, Texas, USA; cat #: 364429) is a synthetic low molecular mass 
compound belonging to the class of imidazoquinolines that potentially and reversibly 
inhibits class 1 PI3K catalytic activity by competing for its ATP-binding sites (Maira, 
2008). NVP-BEZ235 also inhibits mTOR catalytic activity, but does not target other 
protein kinases. It is known to have an inhibitory concentration for 50% inhibition of 
p110activity in breast cancer cell lines: CCL-247, HTB-38 and HTB-20 of ~7 nM 
(Maira et al., 2008). 
  
For this study, a stock solution of 106 mM NVP-BEZ235 was reconstituted in 
dimethyl sulfoxide (DMSO) and stored at -20ºC until needed. To assess the influence 
of inhibitor concentration on cytotoxicity, cells were exposed to final concentrations 
of 0.6–70 nM of NVP-BEZ235.  
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Figure 2.1: Chemical structure of NVP-BEZ235. 
 
2.1.3.2. TAK-165  
Figure 2.2 shows the chemical structure of TAK-165 (C25H23F3N4O2; Mw = 468.47; 
TOCRIS Biosciences, UK; cat #: 3599). TAK-165 is a low molecular mass compound 
that was designed and synthesised by Takeda Pharmaceutical Company, Osaka, 
Japan. Biochemically, TAK-165 selectively inhibits HER2 and EGFR kinase activities 
with inhibitory concentrations of 6 and 25 000 nM for 50% inhibition (Nagasawa et 
al., 2006).  
 
For this study, a stock solution of 21 mM of TAK-165 was prepared in dimethyl 
sulfoxide (DMSO) and stored at -20ºC until used. To assess the influence of inhibitor 
concentration on cytotoxicity, cells were exposed to a final concentration of 0.9–135 
nM of TAK-165.  
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Figure 2.2: Chemical structure of TAK-165. 
 
 
2.1.3.3. ABT-263 
As shown in Figure 2.3, ABT-263 (C47H55ClF3N5O6S3; Mw = 1047.52; gift from the 
Chemotherapeutic Agents Repository of the Drug Synthesis and Chemistry Branch, 
National Cancer Institute, USA) is a Bad-like BH3 mimic for Bcl-2, Bcl-xl, and Bcl-w. 
Biochemically, ABT-263 disrupts Bcl-2/Bcl-xL interactions with pro-death proteins, 
leading to induced apoptosis within 2 hours after treatment. More so, in human 
cancer cells, ABT-263 induces Bax translocation, Cytochrome C release, and 
subsequent apoptosis (Bajwa et al., 2012). The stock solution consisted of 955 µM of 
ABT-263 in dimethyl sulfoxide (DMSO) and was stored at -20ºC until needed. To 
assess the influence of inhibitor concentration on cytotoxicity, cells were exposed to 
final concentrations of 0.03-10 000 nM of ABT-263. 
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Figure 2.3: Chemical structure of ABT-263. 
 
 
2.1.4. Cell Culture Medium 
  
2.1.4.1. Dulbecco’s Modified Eagle’s Medium Nutrient Mixture (F-12 Ham) 
Dulbecco’s modified Eagle’s medium nutrient mixture, F-12 HAM (Sigma-Aldrich, 
USA; cat #: D8437) is a pre-constituted liquid growth medium, supplemented with 15 
mM HEPES, 0.365 gm/L L-glutamine, 1.2 gm/L sodium bicarbonate, 20 ng/ml human 
epidermal growth factor (Sigma-Aldrich, Germany; cat #: E9644), 0.01 mg/ml bovine 
insulin (Sigma-Aldrich, Germany; cat #: I5500), and 500 ng/ml hydrocortisone 
(Sigma-Aldrich, Germany; cat #: H0888). The growth medium was further 
supplemented with 10% heat-inactivated foetal bovine serum (FBS) (HyClone, UK; 
cat #: SV30160.30IH), and penicillin (100 U/ml)/streptomycin (100 µg/ml) (Lonza, 
Belgium; cat #: DE17-602E). 
 
Stellenbosch University  https://scholar.sun.ac.za
37 
 
2.1.4.2. Roswell Park Memorial Institute medium (RPMI-1640) 
The Roswell Park Memorial Institute medium, RPMI-1640 (Sigma-Aldrich, USA; cat 
#: R8758), is also a liquid cell culture medium, supplemented with 0.3 gm/L L-
glutamine and 2.0 gm/L sodium bicarbonate. The growth medium was further 
supplemented with 10% heat-inactivated foetal bovine serum (FBS) (HyClone, UK; 
cat #: SV30160.30IH), and penicillin (100 U/ml)/streptomycin (100 µg/ml) (Lonza, 
Belgium; cat #: DE17-602E). 
 
2.2. Cell Lines 
 
The human breast cell lines (MDA-MD-231, MCF-7 and MCF-12A) used in this study 
exhibit diminished expression of HER2, ER or PR, and have been classified as triple-
negative elsewhere (Chavez et al., 2010; Leung et al., 2014). The rationale for 
choosing these cell lines is that they significantly differ in expression of potential 
target antigens, such as, HER2, ER, PR and EGFR. Although MCF-7 cells are 
EGFR, HER2, ER and PR positive (Horwitz et al., 1975; Rusnak et al., 2001), their 
expression of HER2 is low and comparable to that in the MDA-MB-231 cells 
(Konecny et al., 2006) and MCF-12A cells (Subik et al., 2010). While expression of 
EGFR in MCF-7 cells is also low, MDA-MB-231 and MCF-12A cells which are known 
to be ER and PR negative (Subik et al., 2010), express higher levels of EGFR 
(Konecny et al., 2006; Subik et al., 2010). Furthermore, the MDA-MB-231 and MCF-
12A cell lines express wild-type PI3K, whereas the MCF-7 cell line is PI3K mutant 
(Vasudevan et al., 2009; Carlson et al., 2010). 
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2.2.1. MDA-MB-231 (passage number: 15-30) 
 
The MDA-MB-231 cell line was established from pleural effusions taken from a 51 
year old Caucasian woman with invasive ductal mammary adenocarcinoma, and has 
been classified as a basal-like breast cancer subtype (Subik et al., 2010). It has an 
epithelial-like morphology, is adherent, grows as a monolayer, and forms metastatic 
xenografts in nude mice in an oestrogen-dependent manner. The cells were a gift 
from Professor S. Prince (University of Cape Town, South Africa), and were routinely 
cultured in Roswell Park Memorial Institute medium (RPMI-1640).  
 
2.2.2. MCF-7 (passage number: 20-30) 
 
The MCF-7 cell line was established from pleural effusions taken from a 69 year old 
Caucasian woman with invasive ductal mammary carcinoma, and has been 
classified as a luminal A breast cancer subtype (Subik et al., 2010). It has an 
epithelial-like morphology, is adherent, grows as a monolayer, and forms metastatic 
xenografts in nude mice in an oestrogen-independent manner. The cells were a gift 
from Professor S. Prince (University of Cape Town, South Africa), and were routinely 
cultured in Roswell Park Memorial Institute medium (RPMI-1640).  
 
 
 
2.2.3. MCF-12A (passage number: 20-35) 
 
The apparently normal immortalised mammary epithelial cell line, MCF-12A, was 
derived from mammary gland tissue taken from a 60 year old Caucasian woman and 
was a gift from Professor AM Engelbrecht (Stellenbosch University, South Africa). 
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The cells were routinely cultured in Dulbecco’s modified Eagle’s medium/nutrient F-
12 HAM.  
 
2.2.4. HeLa Cells (passage number: 43) 
 
The HeLa cell line was derived from cervical cancer tissue taken from a 31 year old 
African-American woman. The cells were a gift from Prof E. van Helden 
(Stellenbosch University, South Africa) and were routinely cultured in McCoy’s 5A 
medium (Sigma-Aldrich, South Africa; cat #: M4892).  
2.3. Routine Cell Culture and Cryopreservation 
 
Cell cultures were routinely incubated at 37°C in a humidified atmosphere (95% air 
and 5% CO2) in SHEL LAB incubators (Sheldon Manufacturing Inc., USA). Cells 
were grown as monolayers in 75-cm2 flasks (Greiner Bio-One, Germany; cat #: 
658170) and were used for experiments (passages 1540) upon reaching 7090% 
confluence. 
 
For cryogenic storage, cells were trypsinised, centrifuged (4 000 RPM for 5 minutes), 
and re-suspended in a mixture of 0.9 ml foetal bovine serum and 0.1 ml of dimethyl 
sulfoxide (DMSO) in cryovials. The vials were stored at -80°C overnight, and then 
transferred into liquid nitrogen for use at a later stage. To return cells to culture, the 
frozen cells were re-suspended in the appropriate growth medium and incubated. 
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2.4. Irradiation of Cell Cultures 
 
Cells grown in 25 cm2 tissue culture flasks were initially irradiated using 60Co -rays 
at the Tygerberg Academic Hospital. The beam configuration was vertical with a 
source-to-sample distance (SSD) of 66.5 cm, measured to the base of the 
experimental flasks. The field size was 30 x 30 cm2. Build-up consisted of 10 ml of 
medium in the 25 cm2 culture flasks, and a 0.5 cm perspex sheet positioned on top 
of the culture flasks. The backscatter radiation was absorbed by an 8.5 cm thick 
foamalite slab and a 5 cm thick perspex sheet. The mean dose rate was 0.827 
Gy/min (range: 0.782-0.873 Gy/min). Dosimetry was by thermoluminescent 
dosimetry (TLD chips). 
 
Following the decommissioning of the 60Co -irradiator in December 2014, 
subsequent cell culture irradiation was performed using a Faxitron MultiRad 160 X-
irradiator (Faxitron Bioptics, Tucson, AZ, USA) at the Division of Radiobiology 
(Faculty of Medicine and Health Sciences, Stellenbosch University). Samples were 
irradiated at an SSD of 65 cm, measured to the base of the experimental flasks, at a 
dose rate of 1.0 Gy/min. For this, build-up also consisted of 10 ml of medium in the 
25 cm2 culture flasks. In all cases, cell cultures were irradiated at room temperature 
(22C). 
2.5. Cell Survival Assay and Radiosensitivity 
 
The colony assay was used to measure intrinsic radiation response in all cell lines. 
Cultures in exponential growth were trypsinised to give single-cell suspensions and 
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were plated (500-10 000 cells per flask, adjusted for irradiation dose) into 25 cm2 
culture flasks (Greiner Bio-One, Germany; cat #: 690160), and incubated for 3-4 h to 
allow the cells to attach. Cell cultures were then irradiated to 0-10 Gy with either 60Co 
-rays or X-rays and reincubated. Three flasks were used per dose point. After 
growing for 7-10 days, depending on the cell line, colonies were fixed, stained, 
washed in tap water, air-dried, and counted. Three independent experiments were 
performed for each dose point, and the mean surviving fractions were fitted to the 
linear-quadratic (LQ) model of the form: 
 
𝑆 = exp⁡[−D − 𝐷2]    (1) 
 
to generate survival curves. S is the surviving fraction, α and β are the linear and 
quadratic cell inactivation constants, respectively, and D is the absorbed dose in Gy. 
Cellular radiosensitivity was expressed in terms of the surviving fraction at 2 Gy 
(SF2). 
2.6. Target Inhibitor Toxicity Measurements 
 
Single-cell suspensions were plated (1000-4000 cells per flask) into 25 cm2 culture 
flasks, and incubated for 3-4 h to allow the cells to attach. To assess the influence of 
inhibitor concentration on cytotoxicity, cells were exposed to NVP-BEZ235 (0.6-70 
nM), TAK-165 (0.9-135 nM) and ABT-263 (0.03-10 000 nM), and incubated for 7-10 
days for colony formation. The colonies were fixed, stained, washed in tap water, air-
dried, and counted. To determine the equivalent concentration of each inhibitor for 
50% cell killing (EC50), the surviving fractions (SF) were plotted as a function of 
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log(inhibitor concentration) and were fitted to a 4-parameter logistic equation of the 
form: 
 
𝑆𝐹 = 𝐵 +
𝑇−𝐵
{1−10[(𝑙𝑜𝑔𝐸𝐶50−𝐷)𝐻𝑆}
    (2), 
 
where B and T are the minimum and maximum of the sigmoidal curve, respectively, 
D is the log(inhibitor concentration), and HS is the steepest slope of the curve. Three 
independent experiments were performed for each cell line and dose point. 
2.7. Determination of Radiosensitivity Modification by Target Inhibitors 
 
To investigate the influence of inhibitor exposure on radiosensitivity, attached cells 
were treated with 30 nM of TAK-165 (~1.01.5 times the predetermined EC50 for the 
cell lines), 17 nM of NVP-BEZ235 (~3.44.1 times the predetermined EC50 for the 
cell lines) and 97 nM ABT-263 (~0.41.0EC50 predetermined for the cell lines), or a 
cocktail of both inhibitors at the same concentrations, and irradiated immediately with 
2 or 6 Gy, typical doses per fraction in conventional and hypofractionated 
radiotherapy, respectively. The use of relatively higher concentrations of NVP-
BEZ235 was to ensure adequate inhibition of the dual targets (PI3K and mTOR), as 
these would be expected to present a larger number of binding sites. For each 
experiment, sets of cell culture flasks given inhibitors alone (singly and in 
combination) and unirradiated flasks without inhibitors served as controls for cultures 
irradiated with and without inhibitors, respectively. Inhibitor-treated cell cultures were 
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used as controls for those receiving inhibitors and irradiation to allow for inter-
experimental variations in inhibitor toxicity, as exposures to predetermined 
concentrations do not always yield the expected cell killing. The interaction between 
inhibitors and irradiation at 2 and 6 Gy was expressed as a modifying factor (MFcol), 
which is given by the ratio of surviving fractions (SF) in the absence and presence of 
inhibitors as follows: 
 
𝑀𝐹𝑐𝑜𝑙 =
𝑆𝐹(2⁡𝐺𝑦)
𝑆𝐹([𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟]+2⁡𝐺𝑦)
⁡⁡⁡⁡⁡⁡⁡𝑜𝑟⁡⁡⁡𝑀𝐹𝑐𝑜𝑙 =⁡
𝑆𝐹(6⁡𝐺𝑦)
𝑆𝐹([𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟]+6⁡𝐺𝑦)
⁡  (3). 
 
The criteria for inhibition, no effect, and enhancement of radiosensitivity by inhibitors 
are MFcol < 1.0, MFcol = 1.0 and MFcol > 1.0, respectively. 
2.8. Flow Cytometric Analysis  
 
The MDA-MB-231 cells were used to test whether flow cytometry could be used as a 
surrogate for the clonogenic cell survival assay for rapid screening of potential target 
inhibitors as radiosensitisers. This was achieved by determining treatment-induced 
changes in the levels of the pro-apoptotic protein, Bax. Cell cultures at approximately 
80% confluency were treated with 17 nM of NVP-BEZ235, exposed to 2 Gy of X-
rays, and then incubated for 24 hours. The growth medium was decanted and the 
cell cultures were trypsinised and reconstituted in growth medium to give single-cell 
suspensions. The cells were counted, pelleted and re-suspended in foetal bovine 
serum. Aliquots of 0.9 ml containing 1 000 000 cells each were transferred into flow 
cytometry tubes, and centrifuged at 4 000 RPM for 5 minutes. Cell pellets were re-
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suspended in 100 µl of IC fixation buffer (eBiosciences, CA, USA; cat #: 00-8222) 
and 100 µl permeabilisation buffer (eBiosciences, CA, USA; cat #: 00-8333) for 20 
minutes at 4°C (protected from light). The fixed and permeabilised cells were further 
centrifuged at 500g for 5 minutes and the supernatant discarded. The cells were 
then re-suspended in 500 µl of 10% dimethyl sulfoxide (DMSO) in foetal bovine 
serum (FBS) and stored at -80°C until used.  
 
For intracellular staining, tubes containing frozen cells were retrieved from -80°C, 
thawed at 37°C, centrifuged at 500g for 5 minutes and the supernatant discarded. 
The cells were then washed twice in PBS (centrifuged two times at 500g for 5 min) 
to remove the freezing medium, and fixed and permeabilised again. This re-fixing 
and re-permeabilisation are required prior to staining as the process of 
permeabilisation is reversible over prolonged cryopreservation. This was then 
followed by washing the cells two times with 120 µl of permeabilisation buffer. The 
washed cells in each tube were then resuspended in 500 µl of antibody staining 
solution (2% FBS in PBS) and 5 µl of a mouse anti-human phycoerythrin-conjugated 
antibody, Bax antibody (6D149) PE (Santa Cruz Biotechnology, Texas, USA; cat. #: 
sc-70405).  Samples were then incubated for at least 30 minutes at room 
temperature in the dark before flow cytometric analysis.  
 
Flow cytometry data were acquired using a BD FACSCalibur equipped with 
CellQuest PROTM software (Becton Dickinson, San Jose, CA, USA) and 2 Lasers 
(488 and 633 nm), and a capacity to simultaneously detect up to four fluorescent 
probes. Typically, 10 000 events per sample were collected and analysed using 
FlowJo v.X.0.7 (TreeStar Software, Inc. Ashland, OR, USA). Pro-apoptotic Bax 
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activity was expressed in terms of the mean fluorescence intensity (MFI) of Bax 
antibody (6D149) PE. The MFI-value was then used to derive a radiation modifying 
factor according to the equation: 
 
𝑀𝐹𝑓𝑙𝑜𝑤 =⁡
𝑀𝐹𝐼(𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟⁡+⁡2⁡𝐺𝑦)−⁡𝑀𝐹𝐼(𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟⁡+0⁡𝐺𝑦)⁡
𝑀𝐹𝐼(2⁡𝐺𝑦)−𝑀𝐹𝐼(0⁡𝐺𝑦)
   (4), 
 
and compared with that obtained using the colony forming assay (MFcol). 
 
2.9. Data Analysis  
 
Statistical analyses were performed using the GraphPad Prism (GraphPad Software, 
San Diego, CA, USA.) computer program. For associations, linear regression 
analyses were used. Standard equations were used to fit nonlinear relationships. 
Data were calculated as the means (± SEM) from three independent experiments. 
For each experiment and data point, 3 replicates were assessed. To compare two 
data sets, the unpaired t-test was used. P-values and coefficients of determination, 
R2, were calculated from two-sided tests. A P-value of <0.05 indicated a statistically 
significant difference between the data sets.  
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Chapter Three: Results  
 
3.1. Calibration of Faxitron MultiRad 160 X-irradiator  
 
Human cervical carcinoma cells (HeLa) were used to validate the equivalent 
biological effectiveness of the decommissioned 60Co -irradiator and the newly 
installed Faxitron MultiRad 160 X-irradiator, and to allow direct use of all data 
generated in this study. For this, clonogenic cell survival of HeLa cells was 
determined concurrently following irradiation with the Faxitron MultiRad 160 X-
irradiator and the decommissioned 60Co -irradiator. The data in Figure 3.1 show that 
the cell survival curves for the - and X-irradiation are congruent, indicating that the 
biological effectiveness of the 160 kVp X-rays from the Faxitron MultiRad 160 X-
irradiator does not differ significantly from that of the 60Co -irradiator. It is not 
surprising that the 160 kVp X-rays and 60Co -rays emerged equally effective in cell 
killing. Although the linear energy transfers of 100 – 250 kVp X-rays range between 
~5 and 2 keV/µm, respectively, and are orders of magnitude higher than that of 60Co 
-rays (~0.3 keV/µm), the relative biological effectiveness of these radiation types in 
many biological systems do not differ by greater than 10% (Spadinger and Palcic 
1992; Hering 1986; Nikjoo and Lindborg 2010). 
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Figure 3.1:  The clonogenic cell survival curves for human cervical carcinoma cells when irradiated 
with 
60
Co -rays (black) and Faxitron MultiRad 160 X-rays (green). Each point represents data derived 
from a single experiment consisting of a triplicate of cell culture flasks. 
 
3.2. Intrinsic Radiosensitivity of MDA-MB-231, MCF-7, and MCF-12A Cells 
 
Figure 3.2 shows clonogenic cell survival data for three human breast cell lines 
(MDA-MB-231, MCF-7 and MCF-12A). Intrinsic cellular radiosensitivity expressed in 
terms of the surviving fraction at 2 Gy, SF2. SF2-values were obtained by fitting the 
mean surviving data to the linear-quadratic model. From the cell survival data in 
Figure 3.2, the SF2-values for the MDA-MB-231 (PI3K wild-type), MCF-7 (PI3K 
mutant) and MCF-12A (PI3K wild-type) cell lines were 0.59 ± 0.07, 0.23 ± 0.01, and 
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0.60 ± 0.07, respectively. The MDA-MB-231 and MCF-12A cell lines show a similar 
radiation response at 2 Gy and are deemed radioresistant, whereas the MCF-7 cell 
line is deemed radiosensitive. The radiobiological features of the 3 cell lines are 
summarised in Table 3.1. In general, the cell survival curves did not exhibit 
prominent shoulders, consistent with the almost non-existent β-component of cell kill. 
Therefore, the intrinsic cellular radiosensitivity and the surviving fraction at 6 Gy were 
directly correlated with the -component of cell kill, with the most radiosensitive 
MCF-7 cell line emerging with the largest -coefficient. 
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Figure 3.2: Clonogenic cell survival curves for 3 human breast cell lines after 
60
Co -irradiation. 
Symbols represent the mean surviving fraction ± SEM from three independent experiments. Standard 
errors are not transformed into a logarithmic scale. Survival curves were obtained by fitting 
experimental data to the linear-quadratic model. 
 
Table 3.1: Summary of radiobiological parameters for 3 human breast cell lines (MDA-MB-231, MCF-
7 and MCF-12A). SF2 and SF6 denote the surviving fractions at 2 and 6 Gy, respectively.  and β are 
the linear and quadratic coefficients of cell inactivation, respectively. Data are presented as the mean 
± SEM from 3 independent experiments. 
 
Cell line SF2  SF6  (Gy
-1) β (Gy
-2) 
MDA-MB-231 0.57 ± 0.02 0.128 ± 0.027 0.24 ± 0.03 0.015 ± 0.028 
MCF-7 0.23 ± 0.01  0.096 ± 0.024  0.73 ± 0.09  0.008 ± 0.010  
MCF-12A 0.63 ± 0.05 0.178 ± 0.009  0.23 ± 0.03  0.012 ± 0.004 
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3.3. Cytotoxicity of TAK-165, NVP-BEZ235 and ABT-263 
 
Treatment of cells with inhibitors induced a concentration-dependent cell kill (Figure 
3.3). At cell survival rates ranging from 20-90%, NVP-BEZ235 was clearly more 
potent in cell killing than TAK-165 and ABT-263 in all cell lines. The equivalent 
concentrations of NVP-BEZ235, TAK-165 and ABT-263 for 50% cell survival for the 
MDA-MB-231 cell line were found to be 4.25 ± 0.23 nM (95% CI: 3.784.76 nM),  
28.36 ± 4.65 nM (95% CI: 21.6537.14 nM) and 96.80 ± 9.53 nM (95% CI: 
79.2118.3 nM), respectively. The corresponding EC
50
-values for the MCF-7 cell line 
emerged as 4.15 ± 0.34 nM (95% CI: 3.484.95 nM), 24.87 ± 2.26 nM (95% CI: 
20.4230.30 nM) and 232.2 ± 39.4 nM (95% CI: 163.9328.9 nM). The EC
50
-values 
of NVP-BEZ235, TAK-165 and ABT-263 for the MCF-12A cell line emerged as 5.01 
± 0.81 nM (95% CI: 3.467.23 nM), 20.26 ± 3.84 nM (95% CI: 13.4930.42 nM) and 
112.9 ± 8.8 nM (95% CI: 96.02132.70 nM), respectively. To facilitate comparison, 
the inhibitor toxicity data are summarised in Table 3.2. 
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Figure 3.3: Cytotoxicity curves for HER2 inhibitor (TAK-165: 0.9-135 nM), PI3K and mTOR inhibitor 
(NVP-BEZ235: 0.6-70 nM), and Bcl-2 inhibitor (ABT-263: 0.03-10 000 nM) for 3 human breast cell 
lines (MDA-MB-231, MCF-7 and MCF-12A). Curves were obtained by plotting cell survival as a 
function of log(inhibitor concentration). Cell survival was determined by the colony assay, and data 
were fitted to a 4-parameter logistic equation. Data points are means ± SEM of 3 independent 
experiments. 
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Table 3.2: Summary of cytotoxicity data for 3 human breast cell lines (MDA-MB-231, MCF-7 and 
MCF-12A) treated with HER2 inhibitor (TAK-165), PI3K and mTOR inhibitor (NVP-BEZ235), and Bcl-2 
inhibitor (ABT-263).  EC50 denotes the equivalent concentration for 50% cell survival. T and B are the 
maximum and minimum of the concentration-response curve, respectively (Figure 3.3). HS is the 
steepest slope of the curve. 
 
 
 
  
Cell line Treatment EC50 (nM)  T B HS 
 
MDA-MB-231 
TAK-165 28.36±4.65  1.03±0.03  0.00±0.07  -1.62±0.28  
NVP-BEZ235 4.25±0.23 1.03±0.03 0.10±0.02 -3.14±0.51 
ABT-263  96.80±9.53  1.03±0.02  0.09±0.03  -1.46±0.19  
 
MCF-7 
TAK-165 24.87±2.26  0.98±0.03  0.04±0.05  -2.65±0.58  
NVP-BEZ235 4.15±0.34 1.09±0.03 0.00±0.02 -1.64±0.22 
ABT-263  232.2±39.4 1.01±0.02  0.06±0.04  -0.91±0.12  
 
MCF-12A 
TAK-165 20.26±3.84 1.04±0.05  0.01±0.09  -1.38±0.36  
NVP-BEZ235 5.01±0.81    1.06±0.09 0.00±0.06 -1.01±0.22 
ABT-263  112.9±8.8 1.01±0.02  0.10±0.02  -2.20±0.33  
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3.4. Modulation of Radiosensitivity by TAK-165 and NVP-BEZ235 at 2 Gy  
 
To evaluate the impact of cellular exposure to inhibitors of HER2, PI3K and mTOR 
on radiosensitivity at a relatively low radiation absorbed dose per fraction, based on 
clonogenic cell survival, cell cultures were irradiated to 2 Gy immediately after 
administering TAK-165 and NVP-BEZ235 singly or in combination. As shown in 
Figure 3.4, pre-treatment with the HER2 inhibitor (TAK-165) alone led to a small and 
insignificant radiosensitisation in all cell lines, with SF2 decreasing from 0.57 ± 0.02 
to 0.51 ± 0.03, 0.23 ± 0.01 to 0.22 ± 0.02, and 0.63 ± 0.05 to 0.55 ± 0.01 for the 
MDA-MB-231, MCF-7 and MCF-12A cells, respectively. This correspondingly 
translated to about 11, 4 and 13% increase in radiotoxicity (Table 3.3). On the other 
hand, inhibiting PI3K and mTOR activity with NVP-BEZ235 significantly 
radiosensitised MDA-MB-231 and MCF-7 cells, but not the apparently normal MCF-
12A cells. The resulting SF2-values were 0.32 ± 0.04, 0.14 ± 0.02 and 0.48 ± 0.03 for 
the MDA-MB-231, MCF-7 and MCF-12A cell lines, respectively. The corresponding 
modifying factors were 1.78 ± 0.23, 1.64 ± 0.25 and 1.31 ± 0.13 (Table 3.3). In all 
cases, NVP-BEZ235 was more radiosensitising than TAK-165. Concomitant 
treatment with TAK-165 and NVP-BEZ235, significantly enhanced radiosensitivity in 
all cell lines, yielding ~4-, ~3-, and ~8-fold reduction in cell survival in the MDA-MB-
231, MCF-7 and MCF-12A cell lines, respectively.  
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Figure 3.4:  Clonogenic cell survival at 2 Gy (SF2) for 3 human breast cell lines after irradiation with 
X-rays: MDA-MB-231, MCF-7, and MCF-12A cells were irradiated without or in the presence of TAK-
165 (HER2 inhibitor: 0.9-135 nM) and NVP-BEZ235 (dual inhibitor of PI3K and mTOR: 0.6-70 nM), 
either administered singly or in combination. Bars represent the mean surviving fraction ± SEM from 
three independent experiments. In comparison with SF2 without inhibitors: *P > 0.05; ***P < 0.005.  
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Table 3.3: Summary of radiosensitivity and dose modifying data for three human breast cell lines 
treated with inhibitors TAK-165 (for HER2) and NVP-BEZ235 (for PI3K and mTOR). 
 
Cell line Treatment SF2*  MF2
#  
 
 
MDA-MB-231 
2 Gy  0.57 ± 0.02 
 
2 Gy + TAK-165 0.51 ± 0.03 1.12 ± 0.07 
2 Gy + NVP-BEZ235 0.32 ± 0.04  1.78 ± 0.23  
2 Gy + NVP-BEZ235 + TAK-165  0.15 ± 0.03 3.80 ± 0.77 
 
 
MCF-7 
2 Gy  0.23 ± 0.01 
 
2 Gy + TAK-165 0.22 ± 0.02 1.04 ± 0.11 
2 Gy + NVP-BEZ235 0.14 ± 0.02 1.64 ± 0.25 
2 Gy + NVP-BEZ235 + TAK-165  0.08 ± 0.04 2.88 ± 1.44 
 
 
MCF-12A 
2 Gy  0.63 ± 0.05 
 
2 Gy + TAK-165 0.55 ± 0.01 1.15 ± 0.09 
2 Gy + NVP-BEZ235 0.48 ± 0.03 1.31 ± 0.13 
2 Gy + NVP-BEZ235 + TAK-165  0.08 ± 0.02 7.88 ± 2.07 
SF2 and MF2 denote the surviving fraction and radiation modifying factor at 2 Gy, respectively. *Mean 
± SEM. 
#
Mean ± error: errors were calculated using appropriate error propagation formulae. 
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3.5. Modulation of Radiosensitivity by TAK-165 and NVP-BEZ235 at 6 Gy 
 
To investigate whether radiosensitisation of breast carcinoma cell lines exist at 
higher fractional doses, as may be encountered in stereotactic radiotherapy, the 
effects of blocking the activities of HER2, PI3K and mTOR, and immediately 
irradiating cell cultures to 6 Gy was assessed. The cell survival data are presented in 
Figure 3.5 for the three cell lines. Pre-treatment of MDA-MB-231 cells with the HER2 
inhibitor (TAK-165) appeared to increase radioresistance, whilst treatment with either 
the dual inhibitor of PI3K and mTOR (NVP-BEZ235) alone or in combination with 
TAK-165 resulted in a slight reduction in radiosensitivity (P > 0.38). On the other 
hand, MCF-12A cells were significantly radiosensitised when pre-treated with TAK-
165 and NVP-BEZ235, either singly or as a cocktail, giving radiation modifying 
factors of 2.34 ± 0.39, 2.62 ± 0.93 and 3.24 ± 1.54, respectively. While HER2 
inhibition had no effect on the radiosensitivity of the MCF-7 cell line, inhibition of 
PI3K and mTOR yielded a 12-fold radiosensitisation (Figure 3.5 and Table 3.4). Pre-
treatment with the inhibitor cocktail resulted in a modifying factor of only 2.34 ± 0.68.   
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Figure 3.5: Clonogenic cell survival at 6 Gy (SF6) for 3 human breast cell lines after irradiation with X-
rays: MDA-MB-231, MCF-7, and MCF-12A cells were irradiated without or in the presence of TAK-165 
(HER2 inhibitor: 0.9-135 nM) and NVP-BEZ235 (dual inhibitor of PI3K and mTOR: 0.6-70 nM), either 
administered singly or in combination. Bars represent the mean surviving fraction ± SEM from three 
independent experiments. In comparison with SF6 without inhibitors: *P > 0.05; **0.005 ≤ P ≤ 0.05; 
***P < 0.005.    
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Table 3.4: Summary of radiosensitivity and dose modifying data for three human breast cell lines 
treated with inhibitors TAK-165 (for HER2) and NVP-BEZ235 (for PI3K and mTOR). 
 
Cell line Treatment SF6*  MF6
#  
 
 
MDA-MB-231 
6 Gy  0.128 ± 0.027 
 
6 Gy + TAK-165 0.160 ± 0.025 0.80 ± 0.21 
6 Gy + NVP-BEZ235 0.107 ± 0.020  1.20 ± 0.34 
6 Gy + NVP-BEZ235 + TAK-165  0.093 ± 0.015 1.38 ± 0.37 
 
 
MCF-7 
6 Gy  0.096 ± 0.024 
 
6 Gy + TAK-165 0.102 ± 0.004 0.94 ± 0.24 
6 Gy + NVP-BEZ235 0.008 ± 0.002 12.00 ± 4.24 
6 Gy + NVP-BEZ235 + TAK-165 0.041 ± 0.006 2.34 ± 0.68 
 
 
MCF-12A 
6 Gy  0.178 ± 0.009 
 
6 Gy + TAK-165 0.076 ± 0.012 2.34 ± 0.39 
6 Gy + NVP-BEZ235 0.068 ± 0.024 2.62 ± 0.93 
6 Gy + NVP-BEZ235 + TAK-165  0.055 ± 0.026 3.24 ± 1.54 
SF6 and MF6 denote the surviving fraction and radiation modifying factor at 6 Gy, respectively. *Mean ± 
SEM. 
#
Mean ± error: errors were calculated using appropriate error propagation formulae. 
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3.6. Modulation of Radiosensitivity by NVP-BEZ235 and ABT-263 at 2 Gy 
 
Pre-treatment of MDA-MB-231 cells with Bcl-2 inhibitor, ABT-263, alone or a cocktail 
of ABT-263 and NVP-BEZ235 resulted in significant radiosensitisation, with the latter 
yielding the highest effect (Figure 3.6). The corresponding radiation modifying factors 
emerged as 1.96 ± 0.15 and 4.39 ± 1.69 (Table 3.5). In this cell line, ABT-263 was 
marginally more radiosensitising than NVP-BEZ235. Exposure of MCF-7 cells with 
ABT-263 did not affect their radiosensitivity (Figure 3.6). This was also reflected in 
the observation that addition of ABT-263 had no added benefit in the 
radiosensitisation seen with NVP-BEZ235 alone. For the MCF-12A cell line, 
inhibition of Bcl-2 alone (with ABT-263) was more radiosensitising than when both 
PI3K and mTOR were inhibited (with NVP-BEZ235). The corresponding radiation 
modifying factors were 1.85 ± 0.22 and 1.31 ± 0.13 (P = 0.06). Pre-treatment of 
these cells with both inhibitors yielded a 7-fold radiosensitisation, similar to that 
obtained when MCF-12A cells were pre-treated with a cocktail of TAK-165 and NVP-
BEZ235 (Tables 3.3 and 3.5).  
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Figure 3.6: Clonogenic cell survival at 2 Gy (SF2) for 3 human breast cell lines after irradiation with X-
rays: MDA-MB-231, MCF-7, and MCF-12A cells were irradiated without or in the presence of ABT-263 
(Bcl-2 inhibitor: 0.03-10 000 nM) and NVP-BEZ235 (dual inhibitor of PI3K and mTOR: 0.6-70 nM), 
either administered singly or in combination. Bars represent the mean surviving fraction ± SEM from 
three independent experiments. In comparison with SF2 without inhibitors: *P > 0.05; **0.005 ≤ P ≤ 
0.05; ***P < 0.005.    
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Table 3.5: Summary of radiosensitivity and dose modifying data for three human breast cell lines 
treated with inhibitors ABT-263 (for Bcl-2) and NVP-BEZ235 (for PI3K and mTOR). 
 
Cell line Treatment SF2*  MF2
#  
 
 
MDA-MB-231 
2 Gy  0.57 ± 0.02 
 
2 Gy + ABT-263 0.29 ± 0.02 1.96 ± 0.15 
2 Gy + NVP-BEZ235 0.32 ± 0.04 1.78 ± 0.23 
2 Gy + NVP-BEZ235 + ABT-263  0.13 ± 0.05 4.39 ± 1.69 
 
 
MCF-7 
2 Gy  0.23 ± 0.01 
 
2 Gy + ABT-263 0.24 ± 0.01 0.96 ± 0.06 
2 Gy + NVP-BEZ235 0.14 ± 0.02 1.64 ± 0.25 
2 Gy + NVP-BEZ235 + ABT-263  0.12 ± 0.02 1.92 ± 0.33  
 
 
MCF-12A 
2 Gy  0.63 ± 0.05 
 
2 Gy + ABT-263 0.34 ± 0.03 1.85 ± 0.22 
2 Gy + NVP-BEZ235 0.48 ± 0.03 1.31 ± 0.13 
2 Gy + NVP-BEZ235 + ABT-263  0.09 ± 0.02 7.00 ± 1.65 
SF2 and MF2 denote the surviving fraction and radiation modifying factor at 2 Gy, respectively. *Mean ± 
SEM. 
#
Mean ± error: errors were calculated using appropriate error propagation formulae. 
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3.7. Modulation of Radiosensitivity by ABT-263 and NVP-BEZ235 at 6 Gy 
 
To assess whether blocking the activities of PI3K, mTOR and Bcl-2, with specific 
inhibitors results in changes in cellular radiosensitivity at relatively large fractional 
radiation absorbed doses, cell cultures were treated with NVP-BEZ235 (dual inhibitor 
of PI3K and mTOR), ABT-263 (inhibitor of Bcl-2), or a combination of both inhibitors, 
and immediately irradiated to 6 Gy. In MDA-MB-231, MCF-7 and MCF-12A cell lines, 
inhibition of Bcl-2 with ABT-263 alone led to a significant radiosensitisation (Figure 
3.7). The radiation modifying factors for the cell lines were similar and emerged as 
4.57 ± 1.02, 4.34 ± 0.57 and 4.57 ± 1.16, respectively (Table 3.6). While NVP-
BEZ235 significantly radiosensitised MCF-12A (MF6 = 2.62 ± 0.93) and MCF-7 (MF6 
= 12.00 ± 4.24) cells, its radiomodulatory effect on MDA-MB-231 cells was minimal 
(Figure 3.7). Pre-treatment of cell cultures with a cocktail of ABT-263 and NVP-
BEZ235 yielded a very large radiosensitisation of ~14-fold in the MCF-12A and MDA-
MB-231 cell lines, while a 2-fold radiosensitisation was seen in the MCF-7 cell line 
(Figure 3.7 and Table 3.6).   
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Figure 3.7: Clonogenic cell survival at 6 Gy (SF6) for 3 human breast cell lines after irradiation with X-
rays: MDA-MB-231, MCF-7, and MCF-12A cells were irradiated without or in the presence of ABT-263 
(Bcl-2 inhibitor: 0.03-10 000 nM) and NVP-BEZ235 (dual inhibitor of PI3K and mTOR: 0.6-70 nM), 
either administered singly or in combination. Bars represent the mean surviving fraction ± SEM from 
three independent experiments. In comparison with SF6 without inhibitors: *P > 0.05; **0.005 ≤ P ≤ 
0.05; ***P < 0.005.  
  
Stellenbosch University  https://scholar.sun.ac.za
64 
 
Table 3.6: Summary of radiosensitivity and dose modifying data for three human breast cell lines 
treated with inhibitors ABT-263 (for Bcl-2) and NVP-BEZ235 (for PI3K and mTOR). 
 
Cell line Treatment SF6*  MF6
#  
 
 
MDA-MB-231 
6 Gy  0.128 ± 0.027  
6 Gy + ABT-263 0.028 ± 0.002 4.57 ± 1.02 
6 Gy + NVP-BEZ235 0.107 ± 0.020  1.20 ± 0.34 
6 Gy + NVP-BEZ235 + ABT-263  0.009 ± 0.001 14.22 ± 3.39 
 
 
MCF-7 
6 Gy  0.096 ± 0.024 
 
6 Gy + ABT-263 0.021 ± 0.001 4.57 ± 1.16 
6 Gy + NVP-BEZ235 0.008 ± 0.002 12.00 ± 4.24 
6 Gy + NVP-BEZ235 + ABT-263 0.045 ± 0.004 2.13 ± 0.57 
 
 
MCF-12A 
6 Gy  0.178 ± 0.009 
 
6 Gy + ABT-263 0.041 ± 0.005 4.34 ± 0.57 
6 Gy + NVP-BEZ235 0.068 ± 0.024 2.62 ± 0.93 
6 Gy + NVP-BEZ235 + ABT-263 0.013 ± 0.005 13.69 ± 5.31 
SF6 and MF6 denote the surviving fraction and radiation modifying factor at 6 Gy, respectively. *Mean ± 
SEM. 
#
Mean ± error: errors were calculated using appropriate error propagation formulae. 
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3.8. Summary of Radiomodulation by Specific Inhibitors  
 
To facilitate comparison, radiation modifying factors were plotted against inhibitor 
pre-treatment for the MDA-MB-231, MCF-7 and MCF-12A cells (Figure 3.8). When 
cells were pre-treated with cocktails of TAK-165 and NVP-BEZ235 or ABT-263 and 
NVP-BEZ235, followed by a 2-Gy irradiation, modifying factors of ~4.08.0 were 
observed in the MCF-12A and MDA-MB-231 cell lines, which are low expressers of 
HER2, ER negative, PR negative, and PI3K wild-type (Figure 3.8A). This indicates 
that these cocktails might be beneficial in the management of triple-negative breast 
cancers. MCF-7 cells which are also low expressers of HER2, but ER positive, PR 
positive, and PI3K mutated exhibited corresponding radiation modifying factors of 
~2.03.0 for these treatments. Interestingly, a modifying factor of 12.0 was obtained 
in MCF-7 cells when pre-treated with only NVP-BEZ235 and irradiated to 6 Gy 
(Figure 3.8B). While both inhibitor cocktails yielded only about 2-fold 
radiosensitisation in MCF-7 cells at the higher radiation absorbed dose, large 
modifying factors emerged in the MDA-MB-231 and MCF-12A cells when treated 
with the NVP-BEZ235/ABT-263 cocktail. This suggests that inhibition of PI3K and 
mTOR, or in conjunction with inhibition of Bcl-2 may serve as a means to enhance 
the response of cancers to large fractions of radiation dose. 
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Figure 3.8: Summary of radiomodulation by specific inhibitors in three human breast cell lines (MDA-
MB-231, MCF-7 and MCF-12A) on the basis of radiation modifying factor derived from clonogenic cell 
survival. Treatment codes are denoted as follows: 1 (TAK-165); 2 (ABT-263); 3 (NVP-BEZ235); 4 
(ABT-263 + NVP-BEZ235); and 5 (TAK-165 + NVP-BEZ235). Red ovals indicate modifying factors of 
>4.0 (A) and >12.0 (B). 
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3.9. Inhibitor Interaction 
 
The data in Figure 3.9 represent median-effect plots for MDA-MB-231, MCF-7 and 
MCF-12A cells, treated with NVP-BEZ235, TAK-165 and ABT-263. Inhibitor toxicity 
data were fitted to the function: log(fa/fu) = m×log(D) – m×log(Dm), where fa and fu are 
the affected and unaffected fractions of cells, respectively, and the coefficient m is an 
indicator of the shape of the inhibitor concentration-effect relationship, Dm is the 
median-effect concentration of inhibitor, and D is the concentration of inhibitor (Chou 
2006). Although differences in the shapes of inhibitor concentration-effect curves as 
presented in Figure 3.3 may not be visually obvious, doubling the inhibitor 
concentration should lead to less than 50% increase in effect if the response curve 
follows a hyperbolic shape. The corresponding increase in the case of a flat-
sigmoidal response is much less than for the hyperbolic response. On the other 
hand, if doubling the inhibitor concentration gives more than a 2-fold increase in 
effect, the response curve is classified as sigmoidal. Mathematically, the shape 
parameter m = 1, >1, and <1 for hyperbolic, sigmoidal, and flat-sigmoidal inhibitor 
concentration-effect curves, respectively. Table 3.7 summarises the fitted 
parameters for each inhibitor in each cell line. For NVP-BEZ235 and TAK-165 
treatment, m–values ranged from 1.40  0.12 to 2.18  0.21 indicating sigmoidal 
inhibitor concentration-effect curves. As such, the corresponding Dm–values were 
relatively low and emerged as 4.90  0.18 to 25.36  0.72 nM. On the other hand, 
ABT-263 yielded flat-sigmoidal or hyperbolic concentration-effect curves with m–
values ranging from 0.75  0.10 to 1.10  0.10. This is reflected in the 
correspondingly large Dm–values of 172.59  1.58 to 308.51  1.41 nM. In all cases, 
the correlation coefficients were high and greater than or equal to 0.93, signifying a 
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strong conformity of the data to the mass-action law (Chou 2006). For inhibitors with 
sigmoidal concentration-effect curves, Dm–values were comparable with EC50-values 
(Table 3.2). In contrast, they were found to be significantly larger than the 
corresponding EC50-values following ABT-263 treatment which gave either flat-
sigmoidal or hyperbolic concentration-effect curves. 
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Figure 3.9: Median-effect plots for 3 human breast cell lines, treated with NVP-BEZ235, TAK-165 and 
ABT-263, from toxicity data presented in Figure 3.3. Transformed data were fitted to the function: 
log(fa/fu) = m×log(D) – m×log(Dm), where fa and fu are the affected and unaffected fractions of cells, 
respectively, and the coefficient m is an indicator of the shape of the inhibitor concentration-effect 
relationship (m = 1, >1, and <1 indicate hyperbolic, sigmoidal, and flat-sigmoidal inhibitor 
concentration-effect curves, respectively), Dm is the median-effect concentration of inhibitor, and D is 
the concentration of inhibitor (Chou 2006). Horizontal dotted lines are the median-effect axes.  
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Table 3.7:  Summary of parameters of median-effect plots for HER2 inhibitor (TAK-165), PI3K and 
mTOR inhibitor (NVP-BEZ235), and Bcl-2 inhibitor (ABT-263) in 3 human breast cell lines (MDA-MB-
231, MCF-7 and MCF-12A).  
 
 
 
To interrogate any potential mode of interaction between NVP-BEZ235 and TAK-165 
or NVP-BEZ235 and ABT-263, combination indices (CI) were estimated for each 
cocktail and the fitted parameters listed in Tables 3.2 and 3.7 according to the 
equation: 
 
𝐶𝐼 =
𝐷1
{𝐷𝑚1×(
𝑓𝑎1
1−𝑓𝑎1
)
1
𝑚1}
+⁡
𝐷2
{𝐷𝑚2×(
𝑓𝑎2
1−𝑓𝑎2
)
1
𝑚2}
   (5), 
 
 
Cell line Treatment m  Dm (nM) Shape of 
concentration-
effect curve 
 
MDA-MB-231 
TAK-165 2.16 ± 0.23  24.70 ± 0.73  sigmoidal 
NVP-BEZ235 1.76 ± 0.16 7.29 ± 0.27 sigmoidal 
ABT-263  1.10 ± 0.10 172.59 ± 1.58 hyperbolic 
 
MCF-7 
TAK-165 2.18 ± 0.21  20.50 ± 0.60  sigmoidal 
NVP-BEZ235 2.05 ± 0.11 5.21 ± 0.13 sigmoidal 
ABT-263  0.75 ± 0.05 308.51 ± 1.41 flat-sigmoidal 
 
MCF-12A 
TAK-165 1.71 ± 0.18 25.36 ± 0.73 sigmoidal 
NVP-BEZ235 1.40 ± 0.12    4.90 ± 0.18    sigmoidal 
ABT-263  1.03 ± 0.09 218.36 ± 1.82 hyperbolic 
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 where D1 is the concentration of NVP-BEZ235 and D2 is the concentration of TAK-
165 or ABT-263. m1 and m2 are the respective shape parameters. The 
corresponding median-effect concentrations are denoted as Dm1 and Dm2, fa1 and fa2 
and given as: (1 – SF, as defined in equation (2)). For each cocktail and in all cell 
lines, CI-values were significantly less than 1.0 and ranged from 0.20 – 0.74 (Table 
3.8), indicating synergism for each inhibitor combination at the concentrations used. 
 
 
Table 3.8: Summary of combination indices for PI3K and mTOR inhibitor, NVP-BEZ235 (Agent 1), 
when used at different concentrations (D1, 0.5D1 and 0.25D1) with HER2 inhibitor (TAK-165) or Bcl-2 
inhibitor (ABT-263) in 3 human breast cell lines (MDA-MB-231, MCF-7 and MCF-12A). TAK-165 and 
ABT-263 are denoted as Agent 2 and are at concentrations of 30 and 97 nM, respectively. D1 = 17 
nM.  
 
 
 
 
 
Cell line Agent 2 at D1   at 0.5D1 at 0.25D1 
 
MDA-MB-231 
TAK-165 0.69  0.37  0.19 
ABT-263  0.74 0.41 0.24 
 
MCF-7 
TAK-165 0.61  0.52  0.48 
ABT-263  0.28 0.20 0.15 
 
MCF-12A 
TAK-165 0.22 0.19 0.17 
ABT-263  0.20 0.18 0.16 
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3.10. Flow Cytometry as a Potential Surrogate for the Colony Assay 
 
To test whether flow cytometry could be employed as a rapid screening tool for 
identifying target inhibitors as potential radiosensitisers, MDA-MB-231 cells pre-
treated with NVP-BEZ235 and irradiated to 2 Gy were analysed using flow cytometry 
techniques. Gated cell populations as shown in Figure 3.10A were analysed for their 
incorporation of anti-Bax (6D149) PE (Figure 3.10B). A single experiment was 
performed. The mean fluorescence intensities emerged as 1711 and 1510 for the 
unirradiated cultures in the absence and presence of NVP-BEZ235, respectively. 
The corresponding values for the irradiated cell cultures were found to be 2131 and 
2468. Based on these fluorescence intensities and Equation (4), a radiation 
modifying factor of 2.28 was derived. 
 
 
Figure 3.10: Flow cytometry data: (A) Gated representative dot-plot for MDA-MB-231 cells treated 
with NVP-BEZ235 and subsequently irradiated to 2 Gy of X-rays; (B) Distribution of cellular 
incorporation of anti-Bax (6D149) PE by MDA-MB-231 cells, shown as flow cytometry–generated 
histograms of cellular fluorescence intensity.  
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Chapter four: Discussion 
4.1. Inherent Radiosensitivity  
 
Figure 3.2 shows the cell survival curves for the MCF-7, MDA-MB-231 and MCF-12A 
cell lines used in this study. The MDA-MB-231 and the MCF-12A exhibit similar 
radiation responses at low doses, but marginally differ in radiosensitivity at higher 
doses. On the other hand, the MCF-7 cell line emerged as radiosensitive. The 
observed differences in radiosensitivity cannot be attributed to disparities in 
phosphatase and tensin homolog (PTEN) which impedes PI3K/mTOR pathway 
activity, thereby sensitising cells to cytotoxic insult. PTEN is wildly expressed in all 
cell lines used here (Carlson et al., 2010). While the more radioresistant MDA-MB-
231 and MCF-12A cell lines express wild-type PI3K, the radiosensitive MCF-7 cells 
are PI3K mutant (Carlson et al., 2010; Vasudevan et al., 2009). This may explain the 
relatively high radiosensitivity in the latter cell line. A reduction in PI3K/mTOR 
signalling in MCF-7 cells due to the PI3K mutation can compromise their ability to 
recover from radiation-induced damage. Other genes that play an important role in 
radiosensitivity are the ataxia-telangiectasia mutated (ATM) and tumour suppressor 
gene (p53). The significantly higher radiosensitivity seen in the MCF-7 cells relative 
to their MDA-MB-231 and MCF-12A counterparts cannot also be attributed to 
disparities in their ATM and p53 status. While ATM is not mutated in any of the cell 
lines (Vořechovský et al., 1996; Kenny et al., 2007; Karimi-Busheri et al., 2010), the 
MDA-MB-231 cell carries a mutated p53 (Kenny et al., 2007; Haldar et al., 1994; 
O’Connor et al., 1997; Liu et al., 2001). p53 wild-type cell lines tend to be the most 
radioresistant, with p53 dysfunctional cell lines emerging as the most radiosensitive, 
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while those with mutated p53 exhibit intermediate radiosensitivity (Michie et al., 
2003; Serafin et al., 2003; Akudugu et al., 2004a,b). Therefore, the marked 
radiosensitivity exhibited by the MCF-7 cells is most likely mediated by its mutated 
PI3K or other effectors downstream of the ATM/p53 pathway.    
4.2. Cytotoxicity of Inhibitors of HER2, PI3K, mTOR and Bcl-2 
 
On the basis of clonogenic cell survival, it is demonstrated for MDA-MB-231, MCF-7 
and MCF-12A cells that cytotoxic effects of TAK-165 (HER2 inhibitor), NVP-BEZ235 
(PI3K and mTOR inhibitor), and ABT-263 (Bcl-2 inhibitor) are concentration-
dependent (Figure 3.3). For NVP-BEZ235 treatment, EC50-values of 4.155.01 nM 
were obtained for all cell lines (Table 3.2) and are comparable with PI3K/mTOR 
inhibition data reported elsewhere for MDA-MB-231 and the HER2 amplified breast 
cancer cell lines BT474 and MDA-MB-175-VII (Vasudevan et al., 2009; Carlson et 
al., 2010). In contrast, significantly higher NVP-BEZ235 concentrations for 50% 
growth inhibition (IC50) ranging from 693 nM have emerged for many other breast 
cancer cell lines, with HER2 amplified cell lines tending to be more sensitive 
(Brachmann et al., 2009; Carlson et al., 2010). Interestingly, it was demonstrated 
that doses of NVP-BEZ235 for 50% cell killing (LD50) as high as ~87 and >20 000 nM 
were reported for MDA-MB-231 and MCF-7 cells, respectively (Brachmann et al., 
2009). The disparity in toxicity noted here can be explained by the fact that cell 
growth and metabolic assays, as employed by Brachmann and colleagues, which 
extend over relatively short periods, often tend to overestimate cell survival following 
cytotoxic treatment. Although cell growth and metabolic assays can give general 
cytotoxicity trends, they are snapshots of cellular demise and may not adequately 
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reflect residual cellular reproductive integrity as measured by the colony forming 
assay (Weisenthal et al., 1983); and the resulting LD50-values can be unrealistically 
high. The similarity in NVP-BEZ235 toxicity in MDA-MB-231, MCF-7 and MCF-12A 
cells seems to suggest that NVP-BEZ235-induced cell death cannot be attributed to 
ER-mediation of PI3K activity, as MCF-7 cells are known to exhibit ER-dependent 
PI3K activity while MDA-MB-231 do not (Pozo-Guisado et al., 2002). MCF-12A cells, 
as their MDA-MB-231 counterparts, are ER negative (Subik et al., 2010), and should 
also not be expected to show an ER-mediated PI3K activity.  
 
TAK-165 was generally less potent than NVP-BEZ235, with an EC50–value of 
~2028 nM (Figure 3.3 and Table 3.2). All cell lines minimally express HER2 
(Rusnak et al., 2001; Konecny et al., 2006), and the extensive concentration-
dependent TAK-165 induced cytotoxicity observed here cannot be solely attributed 
to HER2 alone. This finding is likely due to targeting of residual HER2, as well as 
other critical cellular factors. TAK-165 is a potent inhibitor of EGFR and the cell 
division cycle protein 2 homolog (Cdc2), which play a crucial role in cell-cycle 
progression. Perturbation of their activity with TAK-165 can lead to cellular demise 
during cell division. However, the narrow range of toxicity seen here cannot be 
explained by differences in Cdc2 and EGFR activity. Cdc2 activity in MDA-MB-231 is 
intrinsically higher than that in MCF-7 (Pozo-Guisado et al., 2002), indicating a 
stronger dependence of the former cell line on Cdc2 activity for cell cycle 
progression. Inhibiting Cdc2 and the residual HER2 activity with TAK-165 should, 
therefore, be expected to be significantly more toxic in MDA-MB-231 cells than in 
their MCF-7 counterparts. Also, the MDA-MB-231 and MCF-12A cell lines are higher 
expressers of EGFR than the MCF-7 cell line (Konecny et al., 2006; Subik et al., 
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2010). Therefore, larger disparities in cytotoxicities would have emerged had EGFR 
been the critical target of TAK-165. It is also worth noting that the TAK-165 
concentrations used in the current study (0.9 – 135 nM) are much lower than those 
that are typically required to significantly suppress Cdc2 and EGFR activity 
(Nagasawa et al., 2006; Production Technical Information). The IC50 concentrations 
of TAK-165 for Cdc2 and EGFR are 200 and >25 000 nM, respectively. At such high 
concentrations, TAK-165 has been shown to be ~4-fold more inhibitory than 
demonstrated here in a variety of cancer cell lines of bladder, kidney and prostate 
origin in which HER2 expression ranged from weak to high (Nagasawa et al., 2006).  
 
ABT-263 emerged as the least toxic inhibitor, with EC50-values ranging from ~97 
to 232 nM (Figure 3.3 and Table 3.2). These findings are, however, at variance with 
the significantly higher EC50–value of ~1 µM reported elsewhere for a similar panel 
cell lines (Brosseau et al., 2012). The relatively high EC50-value observed by 
Brosseau and colleagues is likely due to the use of a cell growth assay for the 
assessment of cell viability (Brosseau et al., 2012). Cell viability assays often 
overestimate clonogenic cell survival, as not all metabolically active cells are capable 
of forming viable colonies in the longer term (Weisenthal et al., 1983). The rank order 
of EC50-values as listed in Table 3.2 is: MCF-7 > MCF-12A > MDA-MB-231, and 
correlates with Bcl-2 expression of the cell lines. Bcl-2 expression in the MCF-7 cell 
line is higher than that in the MDA-MB-231 cell line, and may be as high as 4.5-fold 
(Kandouz et al., 1996; Brosseau et al., 2012). It is, therefore, not surprising that a 
higher concentration of ABT-263 is required for a 50% cell killing in the MCF-7 cell 
line compared with that for the MDA-MB-231 cell line (Table 3.2).  
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4.3. Radiomodulation by TAK-165 and NVP-BEZ235 
 
In this presentation, it is demonstrated that pre-treatment of all cell lines with TAK-
165 yielded only 415% radiosensitisation at 2 Gy (Figure 3.4 and Table 3.3). This is 
not unexpected, as the cell lines express very low levels of HER2 (Konecny et al., 
2006; Subik et al., 2010). The role of HER2 perturbation in radiosensitivity 
modulation should, therefore, be minimal. This is consistent with data reported 
elsewhere indicating that trastuzumab (a potent HER2 inhibitor) had little or no effect 
on radiation-induced cell death in breast cancer cell lines that show low to no 
expression of HER2 (Liang et al., 2003). However, when cells were pre-treated with 
the dual inhibitor of PI3K and mTOR, moderate radiosensitisation was seen with the 
least radiomodulatory effect emerging in the MCF-12A cell line (Table 3.3). These 
data cannot be explained in terms of PI3K status, as NVP-BEZ235 induced 
radiosensitisation was also noted in the PI3K mutant MCF-7 cell line. The marked 
disparity between the less than 2-fold radiosensitisation observed here and the ~4-
fold radiosensitisation reported elsewhere (Kuger et al., 2014), might be due to 
differences in experiment design. The NVP-BEZ235 concentration of 100 nM used 
by Kuger and colleagues was ~6 times that used in the present study (Kuger et al., 
2014), and corresponds to NVP-BEZ235 doses at which cell survival levels should 
become very low (as depicted in Figure 3.3) if the residence time of the drug was 
over the entire colony forming period. Drug cytotoxicity strongly depends on 
residence time (Akudugu and Slabbert 2008). Also, delayed trypsinisation and re-
plating of cells after drug and radiation treatment can significantly modify the extent 
to which the drugs modulate radiosensitivity. 
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With the exception of the MCF-12A cell line, pre-treatment of cell cultures with TAK-
165 did not yield a measurable radiosensitisation at 6 Gy (Figure 3.5 and Table 3.4). 
The radiosensitisation of MCF-12A cells at a higher radiation dose cannot be 
explained by differences in HER2 expression as it is the MCF-7 cell line that exhibits 
marginally higher expression of this protein (Horwitz et al., 1975; Rusnak et al., 
2001), and radiosensitisation resulting from HER2 inhibition would have been higher 
in the latter cell line. No added benefit was apparent when MCF-12A cells were 
exposed to a TAK-165/NVP-BEZ235 cocktail, suggesting that the effect of targeting 
HER2 and PI3K/mTOR either singly or concurrently in tumours that are low 
expressers of HER2 may be minimal. Neither pre-treatment of MDA-MB-231 cells 
with NVP-BEZ235 nor a cocktail of TAK-165 and NVP-BEZ235 resulted in a 
significant radiosensitisation. Although MDA-MB-231 and MCF-12A cells are PI3K 
wild-type, they are known to be ER and PR negative (Subik et al., 2010). This 
indicates that tumours with signalling features similar to those of these cell lines 
might not benefit from adjuvant hypofractionated radiotherapy with inhibitors of 
HER2, PI3K and mTOR. However, inhibition of PI3K and mTOR in the PI3K-mutated 
MCF-7 cell line resulted in a higher than 8-fold radiosensitisation at 6 Gy (Figure 3.5 
and Table 3.4). The high level of radiosensitisation observed here is at variance with 
the relatively low sensitisation noted when another dual inhibitor of PI3K and mTOR 
(PI-103) was used in the same cell line elsewhere (No et al., 2009). This is likely due 
to the fact that NVP-BEZ235 appears to be a better radiosensitiser than PI-103. 
When umbilical venous endothelial cells and bladder and laryngeal cancer cells were 
pre-treated with the two inhibitors, the former consistently showed higher levels of 
radiosensitisation at 6 Gy, similar to those observed here (Prevo et al., 2008; Fokas 
et al., 2012). The marked radiosensitisation demonstrated for inhibition of PI3K and 
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mTOR in the MCF-7 cell line, and elsewhere (Prevo et al., 2008; Fokas et al., 2012; 
Kuger et al., 2014) cannot be attributed to differences in PI3K status. Using two PI3K 
wild-type colon cancer cell lines and their mutant derivatives, Prevo and colleagues 
demonstrated no significant difference in radiosensitisation by the PI3K and mTOR 
inhibitor, PI-103 (Prevo et al., 2008). However, a predominantly common feature of 
the MCF-7 cell line and those used elsewhere (Prevo et al., 2008; Fokas et al., 2012) 
is that they are oestrogen receptor (ER) positive (Horwitz et al., 1975; Shen et al., 
2006; Toth et al., 2008). The high levels of radiosensitisation seen in these cell lines 
following NVP-BEZ235 treatment may be attributed to inhibition of an enhanced ER-
mediation of PI3K activity. ER-dependent activation of PI3K has been demonstrated 
in MCF-7 cells (Pozo-Guisado et al., 2004). Upregulation of PI3K activity would be 
expected to render cells more susceptible to radiation-induced death when such 
activity is inhibited. These data strongly suggest that inhibition of PI3K and mTOR in 
tumours that are devoid of HER2, PR and ER activity (e.g. triple-negative breast 
cancers), as well as in those that are devoid of only HER2, might sensitise them to 
radiotherapy regimens that employ fractional doses of the order of 6 Gy. 
Furthermore, the results do not demonstrate a benefit for concomitant inhibition of 
residual HER2. HER2 targeting would, therefore, not be necessary and systemic 
toxicity that otherwise arises from such treatment could potentially be avoided.  
 
Of specific note is the marked radiosensitisation observed in the MCF-12A cell line at 
2 Gy when cells were pre-treated with the inhibitor cocktail (Table 3.3). It is not likely 
that the inhibitory activity of the TAK-165/NVP-BEZ235 is directed towards ER and 
PR, as suggested elsewhere (Pozo-Guisado et al., 2002; 2004), since 
radiosensitisation was found to be higher in the ER-negative and PR-negative cell 
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lines (MDA-MB-231 and MCF-12A) than the ER and PR overexpressing MCF-7 cell 
line (Konecny et al., 2006; Subik et al., 2010). These findings seem to suggest that 
the activity of the TAK-165/NVP-BEZ235 cocktail may be specific for other targets, 
such as EGFR, which is often overexpressed by cells with compromised activity of 
HER2, ER and PR (Siziopikou and Cobleigh, 2007). In fact, the rank order of EGFR 
expression in the three cell lines is: MCF-7 < MDA-MB-231 < MCF-12A (Konecny et 
al., 2006; Subik et al., 2010), and is strongly correlated with the extent of radiation 
dose modification (Table 3.3). A similar trend is apparent at 6 Gy, although the level 
of radiosensitisation was much lower (Table 3.4). Therefore, EGFR is a likely target 
for a TAK-165/NVP-BEZ235 cocktail adjuvant therapy at low to moderate radiation 
absorbed doses. This notion can be supported by the observation that simultaneous 
inhibition of EGFR and PI3K can lead to significant radiosensitisation of breast 
cancer cells (Li et al., 2012). In spite of the promising observations, concomitant use 
of TAK-165 and NVP-BEZ235, either singly or as a cocktail, and radiation could 
potentially elevate normal tissue toxicity and requires further evaluation. 
 
4.4. Radiomodulation by NVP-BEZ235 and ABT-263  
 
While inhibition of Bcl-2 with ABT-263 had no effect on the radiosensitivity of the 
MCF-7 cell line at 2 Gy, moderate radiosensitisation was seen in the MDA-MB-231 
and MCF-12A cells (Figure 3.6 and Table 3.5). These data are consistent with other 
studies demonstrating that Bcl-2 inhibitors are potent in Herceptin resistant breast 
cells (Crawford and Nahta, 2011), and can radiosensitise small-cell lung carcinomas 
(Loriot et al., 2014). The absence of a radiomodulatory effect in the MCF-7 cell line 
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might be due to the use of a suboptimal concentration of ~0.4  EC50, given that 
these cells express as high as 4.5-fold Bcl-2 in comparison with the MDA-MB-231 
cells (Kandouz et al., 1996; Brosseau et al., 2012).   
 
As demonstrated for the TAK-165/NVP-BEZ235 cocktail, a strong correlation is also 
evident between radiosensitisation by the ABT-263/NVP-BEZ235 cocktail and EGFR 
expression. The rank order of radiation modifying factors at 2 Gy is: MCF-12A > 
MDA-MB-231 > MCF-7 (Table 3.5), and is consistent with the order of EGFR 
expression (Konecny et al., 2006; Subik et al., 2010). As indicated earlier, the low 
radiosensitisation seen in the MCF-7 cells may be attributable to an inadequate 
inhibition of Bcl-2 (concentration of ~0.4  EC50 used).  
 
At 6 Gy, however, no difference exists in the radiomodulatory effect of ABT-263, with 
all cell lines showing a ~4-fold radiosensitisation (Figure 3.7 and Table 3.6). This 
cannot be explained by the marked differences in Bcl-2 expression (Kandouz et al., 
1996; Brosseau et al., 2012), and seems to suggest that the extent of Bcl-2 
expression may play an important role in ABT-263 induced radiosensitisation only at 
low radiation doses. The large modifying factors seen in the MDA-MB-231 and MCF-
12A cell lines when treated with an ABT-263/NVP-BEZ235 cocktail can be attributed 
to the interrelationship between Bcl-2 and PI3K activities. There is evidence to 
suggest that inhibition of PI3K blocks Bcl-2 expression (Jin et al., 2004). A high level 
of synergy has also been demonstrated for concomitant inhibition of PI3K and Bcl-2 
(Rahmani et al., 2012). Therefore, it can be expected that the concurrent inhibition of 
PI3K and Bcl-2 would lead to significant radiosensitisation even if suboptimal 
concentrations of the Bcl-2 inhibitor are used. It is also worth noting that the rank 
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order in radiosensitisation observed at 2 Gy for the ABT-263/NVP-BEZ235 cocktail 
appeared to be retained at 6 Gy, although the corresponding levels of 
radiomodulation were much higher (Tables 3.5 and 3.6). This further supports the 
suggestion that the activity of this inhibitor cocktail may be mediated by EGFR. It 
may be recalled that EGFR expression is low in the ER- and PR-positive MCF-7 cell 
line (Horwitz et al., 1975; Rusnak et al., 2001), and the ER- and PR-negative cell 
lines (MDA-MB-231 and MCF-12A) are high expressers of EGFR (Konecny et al., 
2006; Subik., et al., 2010). An interesting observation is that both NVP-BEZ235/TAK-
165 and NVP-BEZ235/ABT-263 cocktails yielded significantly lower levels of 
radiosensitisation in the MCF-7 cells at 6 Gy than when cells were pre-treated with 
NVP-BEZ235 and ABT-263 alone (Tables 3.4 and 3.6). This does not corroborate 
the synergy demonstrated by the components of these cocktails in Table 3.8. 
However, this finding is attributed to the fact that radiosensitisers can act as 
antagonists against each other, and their net radiosensitising effects as cocktails 
often fall below the sum of the individual effects (Millar et al., 1981). It is possible that 
in the MCF-7 cell system, the presence of either TAK-165 or ABT-263 negates the 
high radiosensitising effect of NVP-BEZ235. Nonetheless, the data presented here 
suggest that concomitantly targeting Bcl-2, PI3K and mTOR may be clinically 
beneficial in some cancers. Further evaluation of these targets in a broader panel of 
cell lines is desirable.  
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 4.5. Inhibitor Interaction  
 
The combination indices (CI) for the NVP-BEZ235/TAK-165 and NVP-BEZ235/ABT-
263 cocktails for all cell lines ranged between 0.20 and 0.74,  indicating synergism 
for each inhibitor combination (Chou 2006). This might explain the more than 
additive enhancement of radiosensitivity seen in all cell lines. The rank order of 
synergism for both cocktails in the cell lines is: MCF-12A > MCF-7 > MDA-MB-231, 
suggesting that the unique cellular features might play a role in inhibitor cocktail 
cytotoxicity. According to the classification by Chou (Chou 2006), a strong synergism 
(CI range: 0.10.3) emerged in the MCF-12A cell line for both inhibitor cocktails and 
in the MCF-7 cell line for the NVP-BEZ235/ABT-263 cocktail (Table 3.8, at D1). This 
suggests that treatment of tumours with characteristics akin to those of MCF-12A 
(e.g. triple-negative tumours) with either cocktail may be beneficial. As systemic 
toxicity is a significant concern in the clinic and lower drug doses are desirable, 
combination indices were further estimated for each cocktail at reduced NVP-
BEZ235 concentrations keeping those of TAK-165 and ABT-263 constant. The CI-
values listed in Table 3.8 show an improvement in synergism in all cases. It is, 
therefore, likely that the radiosensitisation demonstrated here might persist even at 
low inhibitor concentrations and should be investigated further. 
 
4.6. Flow Cytometry as a Potential Rapid Screening Tool  
 
The clonogenic cell survival assay, although widely accepted as the gold standard 
for cytotoxicity studies, can be expensive and laborious. In most cases, data may 
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become available only after 1-2 weeks. Besides, it is difficult and almost impossible 
to successfully generate colonies from clinically relevant biological material, such as, 
biopsies. This is one of the biggest challenges encountered in attempting to progress 
towards personalised cancer management. To partially address this issue, high 
throughput assays for diagnosing diseases, predicting treatment outcome, and 
testing the efficacy of new therapeutic agents (e.g. drugs and small molecule 
inhibitors) needs to be developed. Although flow cytometry has been evaluated for 
this purpose over the past few decades, most of the efforts have been directed 
towards haematopoietic malignancies (Ross et al., 1989; Siena et al., 1991; Edwards 
et al., 2001; Suzuki 2004; Krutzik and Nolan 2006; Krutzik et al., 2008; Bendall et al., 
2011; Terwijn et al., 2013; Paiva et al., 2014; Bulian et al., 2014). As such, biological 
samples have predominantly been from peripheral blood or suspension cultures 
which are usually not amenable to the clonogenic cell survival assay. High 
throughput techniques enabling such predictions for solid tumours are not well 
developed. As a preliminary effort, flow cytometry was used to test whether the 
radiomodulatory effect of the dual inhibitor of PI3K and mTOR (NVP-BEZ235), as 
determined via the colony forming assay, can be predicted more rapidly. Radiation 
modifying factors of 1.78 and 2.28 were obtained for the clonogenic and flow 
cytometric assays, respectively. The closeness of these factors demonstrates that 
the concept of potentially replacing the colony forming assay with flow cytometry for 
screening therapeutic agents of relevance to solid tumours might be viable. This 
finding may be coincidental, but if validated with a large panel of cell lines the 
proposed approach may be amenable to clinical samples like tumour biopsies, and 
can significantly assist in patient staging for therapy.   
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Chapter five: Conclusions 
 
 This study demonstrates that inhibition of PI3K and mTOR, HER2, and Bcl-2, using 
the respective inhibitors NVP-BEZ235, TAK-165 and ABT-263, either singly or when 
NVP-BEZ235 is combined with TAK-165 or ABT-263, can significantly radiosensitise 
human breast cancer cell lines with differing HER2, ER, PR, and EGFR expression 
levels at 2 Gy. On the basis of clonogenic cell survival, radiosensitisation is more 
prominent in ER- and PR-negative cells expressing higher levels of EGFR. These 
findings suggest that a cocktail of NVP-BEZ235 and TAK-165 or NVP-BEZ235 and 
ABT-263 may have the potential for more effectively targeting triple-negative breast 
cancer cells.  
At 6 Gy, moderate to high radiosensitisation was demonstrated for most inhibitor 
combinations. The only treatments that did not result in a significant 
radiosensitisation were: TAK-165 (in MDA-MB-231 and MCF-12A cells), NVP-
BEZ235 (in MDA-MB-231 cells) and NVP-BEZ235/TAK-165 cocktail (in MDA-MB-
231 cells). In general, these findings show that inhibition of residual HER2, PI3K, 
mTOR, and Bcl-2, singly or in combination, can enhance the effectiveness of 
stereotactic radiotherapy of cancers that are devoid of HER2, ER and PR 
expression. 
 
The radiation modifying effect of inhibitor treatment as measured by flow cytometric 
assessment of Bax expression was comparable with that obtained using the colony 
forming assay. This suggests that, with some level of validation, flow cytometry can 
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be used as a rapid and high throughput assay for evaluating clinical samples, such 
as blood and tumour biopsies, for pretreatment patient staging. 
 
With regards to the NVP-BEZ235/TAK-165 and NVP-BEZ235/ABT-263 cocktails, it 
was demonstrated that synergism exists for each combination. The MCF-12A cell 
line which mimics triple-negative cancers more closely showed the strongest 
synergism for both cocktails. This finding suggests that either combination of 
inhibitors could potentially be beneficial in the management of triple-negative breast 
cancer. An interesting observation is that the strong synergy is maintained even at 
reduced concentration of NVP-BEZ235, indicating that these cocktails could be used 
at a minimised risk of systemic toxicity.  
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Future Avenues 
 
Triple-negative breast cancers (TNBC) pose a major challenge to clinicians. This is 
due to the heterogeneous nature of TNBC and the absence of well-defined 
molecular targets. This is further exacerbated by the fact that triple-negative breast 
cancers consist of six subtypes: two basal-like, an immunomodulatory, a 
mesenchymal, a mesenchymal stem–like, and a luminal androgen receptor. The 
findings of this study show that a cocktail of specific inhibitors may be an approach in 
the treatment of TNBC. The results further indicate that radiosensitisation by the 
different inhibitors, either singly or in combination, varies significantly among the cell 
lines. The disparities between these cell lines may be due to their different 
expression of targeted proteins. Using a panel of TNBC cell lines, Lehmann and co-
workers pharmacologically targeted prominent signalling pathways and found that 
sensitivity to targeted therapies was correlated to gene expression signatures of the 
different TNBC subtypes (Lehmann et al., 2011). They also found that the 
mesenchymal stem-like (MSL) subtype is enriched in gene expression profiles for 
the epithelial-mesenchymal transition and growth factor pathways. The MSL subtype 
is also rich in genes associated with stem cells, such as, the Bcl-2. MSL cells 
responded favourably to NVP-BEZ235 and Dasatinib (an abl/src inhibitor) (Lehmann 
et al., 2011). In the study reported here, the MDA-MB-231 cell line is mesenchymal 
stem-like and the corresponding data for NVP-BEZ235 and ABT-263 combinations 
are encouraging. So are the data for the MCF-7 and MCF-12A cell lines.  
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In light of the above, further research avenues involving a larger panel of cell lines 
representing the different subtypes of TNBC, as well as normal breast cell models, 
and covering a wider range of gene expression profiles are warranted. These could 
guide cocktail selection for specific targeted therapies, as well as, assist in the 
identification of agents that may selectively radiosensitise tumours of each TNBC 
subtype. In addition to validating the current in vitro findings in a larger panel of cell 
lines, the research should be extended to a preclinical level using an in vivo mouse 
xenograft model. This could be achieved by use of state-of-the-art small animal 
irradiation platforms with capacity for volumetric assessment and bioluminescence 
imaging as described elsewhere (Song et al., 2010; Verhaegen et al., 2011; 
Butterworth et al., 2015). 
 
Specifically, the following should be considered:  
 Inhibitor validation at a molecular level using western blotting.  
 Assessment of radiomodulatory effects of the inhibitors for full cell survival-
dose response curves. 
 Evaluation of the impact of a TAK-165 and ABT-263 combination on 
radiosensitivity. 
 Assessment of additional time points for irradiation after inhibitor treatment 
would also be of significant value in understanding the mode of action of 
combination therapy.  
 Small animal studies, using state-of-the-art irradiation and imaging facilities, 
as described elsewhere (Song et al., 2010; Verhaegen et al., 2011; 
Butterworth et al., 2015), would significantly strengthen future studies. 
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 Assessment of the impact of dose fractionation on radiomodulatory effects of 
inhibitors, as radiotherapy is seldom given in a single fraction.  
 Measurement of DNA damage foci by H2AX immunofluorescence assay 
would also assist in understanding the mechanisms underlying the 
radiomodulatory effect of inhibitors. 
 Validation of the finding that flow cytometry might replace the clonogenic cell 
survival as a rapid high throughput tool for evaluating candidate target 
inhibitors for therapeutic benefit in a large panel of cell lines, using a Bland-
Altman type analysis (Giavarina 2015), would be useful. 
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A Cocktail of Specific Inhibitors of HER-2, PI3K, and 
mTOR Radiosensitises Human Breast Cancer Cells 
Introduction
Many subtypes of breast cancer exist and exhibit 
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Abstract
Intrinsic tumour radioresistance limits the benefit of radiotherapy. Targeted treatment modalities that are singly 
effective for triple-negative breast cancer are lacking, partly due to paucity of relevant targets as they are devoid 
of the human epidermal growth factor receptor 2 (HER-2), progesterone receptor (PR), and oestrogen receptor 
(ER); or to resistance to single-target therapies as a consequence of cellular heterogeneity. Concomitant targeting 
of cell signaling entities other than HER-2, PR and ER may sensitise triple-negative tumours to radiotherapy. In 
this study, we investigated the effect of an HER-2 inhibitor (TAK-165) and a dual inhibitor of phosphoinositide 
3-kinase (PI3K) and mammalian target for rapamycin (mTOR) (NVP-BEZ235) in three human breast cancer cell 
lines. The potential of simultaneous inhibition of HER-2, PI3K and mTOR with a cocktail of the specific inhibitors 
TAK-165 and NVP-BEZ235, to radiosensitise human breast cancer cells in vitro was examined using the colony 
forming assay. Combined inhibition of HER-2, PI3K, and mTOR resulted in significant radiosensitisation in all cell 
lines, independent of HER-2, ER, or PR status. Radiosensitisation was more prominent in ER- and PR-negative 
cells expressing higher levels of epidermal growth factor receptor (EGFR). These data suggest that a cocktail of 
TAK-165 and NVP-BEZ235 could potentially be effective in the treatment of triple-negative breast cancer. 
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unique characteristics. Different, as well as, specific 
treatment modalities would be required to benefit 
all subgroups. Cancers overexpressing the gene 
encoding the human epidermal growth factor receptor 
2 (HER-2) constitute 30% of invasive breast cancers 
[1]. Approaches for targeting HER-2 are important in 
the treatment of breast cancers overexpressing HER-2. 
Although trastuzumab has been approved by the United 
States Food and Drug Administration (US FDA) for the 
treatment of HER-2 positive cancers, a significant level 
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of resistance to trastuzumab treatment is apparent 
[2]. Dysregulation of downstream components of 
the HER-2 signaling pathway have been suggested 
to be responsible for the observed resistance [2]. 
Such resistance may also be partly attributable to 
the heterogeneity in the distribution of target antigen 
expression in a given cell population, which can lead to 
the inability to effectively target all cells with toxic levels 
of therapeutic agents [3]. Another challenge is that 
some HER-2 positive cancers express a constitutively 
active truncated form of the protein (p95 HER-2) which 
does not possess the extracellular domain required for 
trastuzumab binding [4], and HER-2 targeted treatment 
may fail. 
Also, about one-fifth of women with breast cancer 
constitutes the subgroup of patients with triple-negative 
breast cancer [5]. This subtype of breast cancer is 
known to occur more frequently in young Black and 
Hispanic women than in young women of other racial 
or ethnic groups [6]. Triple-negative breast cancers lack 
expression of HER-2, progesterone receptor (PR), and 
oestrogen receptor (ER), all of which are promising 
candidates for targeted therapy. Therefore, patients 
with triple-negative tumours cannot be treated with 
endocrine based therapy or therapies targeting HER-2, 
and treatment outcome in these individuals is relatively 
poor [7]. To improve the management of triple-negative 
breast cancer, effective targeting of malignant cells 
devoid of ER, PR, and HER-2 expression is warranted.
 
An alternative treatment modality for breast cancer is 
radiotherapy. Cellular exposure to ionising radiation is 
known to activate the epidermal growth factor receptor, 
EGFR [8], and induce phosphoinositide 3-kinase (PI3K), 
serine-threonine protein kinase (Akt) and mammalian 
target for rapamycin (mTOR) activity downstream of the 
EGFR signaling pathway [9]. This signaling promotes 
cell survival and can lead to treatment resistance. 
Targeting the HER-2 pathway by inhibiting PI3K has also 
been shown to result in significant radiosensitisation 
[10]. Of significance to targeted therapy, triple-negative 
breast cancers, which are devoid of HER-2 activity, tend 
to predominantly overexpress EGFR [11]. Therefore, 
developing therapeutic approaches that concomitantly 
target EGFR family members and their downstream 
signaling components might significantly sensitise 
triple-negative breast cancer cells to radiotherapy and 
improve treatment outcome.
In the present work, studies were conducted to 
determine if inhibition of HER-2, PI3K and mTOR can 
radiosensitise human breast cancer cells. To achieve 
this, MDA-MB-231, MCF-7 and MCF-12A cells were 
treated with TAK-165 (an HER-2 inhibitor) and NVP-
BEZ235 (a dual inhibitor of PI3K and mTOR) and 
concomitantly irradiated, and radiation-induced cell 
death was measured using the colony forming assay. 
The dependence of radiosensitisation on HER-2, 
ER and PR expression status and the implications of 
inhibiting the HER-2/PI3K/mTOR pathway in irradiated 
breast cancer cell lines are also discussed.
Materials and Methods
Cell lines and culture maintenance
The MDA-MB-231 and MCF-7 human breast tumour 
cells were derived from pleural effusions taken from 
women with invasive ductal adenocarcinoma and 
carcinoma, respectively, and were a gift from Prof S 
Prince (University of Cape Town, South Africa). They 
respectively form metastatic xenografts in nude mice 
in an oestrogen-independent and dependent manner. 
The immortalised mammary epithelial cell line, MCF-
12A, was a gift from Prof AM Engelbrecht (University 
of Stellenbosch, South Africa). The rationale for 
choosing these cell lines is that they significantly 
differ in expression of potential target antigens, such 
as, HER-2, ER, PR and EGFR. Although MCF-7 cells 
are EGFR, HER-2, ER and PR positive [12,13], their 
expression of HER-2 is low and comparable to that in 
the MDA-MB-231 cells [14] and MCF-12A cells [15]. 
While expression of EGFR in MCF-7 cells is also low, 
MDA-MB-231 and MCF-12A cells which are known 
to be ER and PR negative [15], express higher levels 
of EGFR [14,15]. Furthermore, the MDA-MB-231 and 
MCF-12A cell lines express wild-type PI3K, whereas 
the MCF-7 cell line is PI3K mutant [16,17]. The MDA-
MB-231 and MCF-7 cell lines were routinely cultured in 
Roswell Park Memorial Institute (RPMI-1640) medium 
(Sigma-Aldrich, USA). MCF-12A cells were cultured in 
Dulbecco’s Modified Eagle medium (DMEM) nutrient 
mixture F-12 Ham (Sigma-Aldrich, USA), supplemented 
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with 20 ng/ml human epidermal growth factor (Sigma-
Aldrich, Germany, cat # E9644), 0.01 mg/ml bovine 
insulin (Sigma-Aldrich, Germany, cat # I5500), and 500 
ng/ml hydrocortisone (Sigma-Aldrich, Germany, cat # 
H0888). All growth media were further supplemented 
with 10% heat-inactivated foetal bovine serum (FBS) 
(HyClone, UK), penicillin (100 U/ml), and streptomycin 
(100 µg/ml) (Lonza, Belgium). Cell cultures were 
routinely incubated at 37°C in a humidified atmosphere 
(95% air and 5% CO2). Cells were grown as monolayers 
in 75-cm2 flasks (Greiner Bio-One, Germany, cat # 
658170) and were used for experiments (passages 18-
39) upon reaching 80-90% confluence.
Target inhibitors
TAK-165 (Tocris Bioscience, UK, cat # 3599) is a 
specific inhibitor of HER-2. NVP-BEZ235 is a dual 
inhibitor of PI3K and mTOR (Santa Cruz Biotechnology, 
TX, USA, cat # 364429). Stock solutions of TAK-165 
(21 mM) and NVP-BEZ235 (106 mM) were prepared 
in dimethyl sulfoxide and stored at 4°C and -20°C, 
respectively, until used. 
Cell survival assay and radiosensitivity
The colony assay was used to measure intrinsic 
radiation response in all cell lines. Cultures in exponential 
growth were trypsinised to give single-cell suspensions 
and were plated (500-10000 cells per flask, adjusted 
for irradiation dose) into 25 cm2 culture flasks (Greiner 
Bio-One, Germany, cat # 690160), and incubated for 
3-4 h to allow the cells to attach. Cell cultures were then 
irradiated to 0-10 Gy with 60Co γ-rays and reincubated. 
The mean dose rate used in this investigation was 
0.83 Gy/min (range: 0.78-0.87 Gy/min). Cultures were 
irradiated at room temperature (22°C). After growing 
for 7-10 days, depending on the cell line, colonies 
were fixed in glacial acetic acid:methanol:water (1:1:8, 
v/v/v), stained with 0.01% amido black in fixative, 
washed in tap water, air-dried, and were counted. Three 
independent experiments were performed for each 
dose point, and the mean surviving fractions were fitted 
to the linear-quadratic (LQ) model to generate survival 
curves. Cellular radiosensitivity was expressed in terms 
of the surviving fraction at 2 Gy (SF2).
Target inhibitor toxicity measurements 
Single-cell suspensions were plated (1000-4000 
cells per flask) into 25 cm2 culture flasks, and incubated 
for 3-4 h to allow the cells to attach. To assess the 
influence of inhibitor concentration on cytotoxicity, 
cells were exposed to TAK-165 (3.7-137.4 nM) and 
NVP-BEZ235 (0.6-69.2 nM) and incubated for 7-10 
days for colony formation. The colonies were fixed in 
glacial acetic acid:methanol:water (1:1:8, by volume), 
stained with 0.01% amido black in fixative, washed 
in tap water, air-dried, and counted. To determine the 
equivalent concentration of each inhibitor for 50% cell 
kill (EC50), the surviving fractions (SF) were plotted as 
a function of log(inhibitor concentration) and were fitted 
to a 4-parameter logistic equation of the form:
   (1),
where B and T are the minimum and maximum of 
the sigmoidal curve, respectively, X is the log(inhibitor 
concentration), and HS is the steepest slope of the 
curve. Three independent experiments were performed 
for each cell line and dose point.
Determination of radiosensitivity 
modification by TAK-165 and NVP-
BEZ235 
To investigate the influence of inhibitor exposure on 
radiosensitivity, attached cells were treated with 30 nM 
of TAK-165 (~EC50 predetermined for MDA-MB-231 and 
MCF-7 cell lines) and 17 nM of NVP-BEZ235 (~4 × EC50 
for MDA-MB-231 and MCF-7 cell lines), or a cocktail 
of both inhibitors at the same concentrations, and 
irradiated immediately with 2 Gy, the typical dose per 
fraction in conventional radiotherapy, using 60Co γ-rays. 
The use of a relatively high NVP-BEZ235 concentration 
was to ensure adequate inhibition of the dual targets, as 
these would be expected to present a larger number of 
binding sites. For each experiment, sets of cell culture 
flasks given inhibitors alone (singly and in combination) 
and unirradiated flasks without inhibitors served 
as controls for cultures irradiated with and without 
inhibitors, respectively. Inhibitor-treated cell cultures 
were used as controls for those receiving inhibitors 
and irradiation to allow for interexperimental variations 
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in inhibitor toxicity, as exposures to predetermined 
concentrations do not always yield the expected cell 
kill. The interaction between inhibitors and γ-irradiation 
(2 Gy) was expressed as a modifying factor (MF), which 
is given by the ratio of surviving fractions (SF) in the 
absence and presence of inhibitors as follows:
   (2).
The criteria for inhibition, no effect, and enhancement 
of radiosensitivity by inhibitors are MF<1.0, MF=1.0 
and MF>1.0, respectively.
Data analysis
Statistical analyses were performed using the 
GraphPad Prism (GraphPad Software, San Diego, 
CA, USA.) computer program. Standard equations 
were used to fit nonlinear relationships. Data were 
calculated as the means (± SE) from three independent 
experiments. For each experiment and data point, 3 
replicates were assessed. To compare two data sets, 
the unpaired t-test was used. P-values and coefficients 
of determination, R2, were calculated from two-sided 
tests. A P-value of <0.05 indicates a statistically 
significant difference between the data sets. 
Results
Intrinsic radiosensitivity of MDA-
MB-231, MCF-7, and MCF-12A cells
Cellular radiosensitivity expressed in terms of the 
SF2 was determined from clonogenic cell survival data 
(Figure 1). SF2-values were obtained by fitting the mean 
surviving data to the linear-quadratic model. From the 
cell survival data in Table 1, the intrinsic SF2-values 
for the MDA-MB-231 (PI3K wild-type), MCF-7 (PI3K 
mutant) and MCF-12A (PI3K wild-type) emerged as 
0.59 ± 0.07, 0.23 ± 0.01, and 0.60 ± 0.07, respectively. 
The MDA-MB-231 and MCF-12A cell lines show 
similar radiation response at 2 Gy and are deemed 
radioresistant, whereas the MCF-7 cell line is deemed 
radiosensitive.
Cytotoxicity of TAK-165 and NVP-BEZ235 
Treatment of cells with inhibitors alone induced a 
concentration-dependent cell kill (Figure 2). At cell 
survival rates ranging from 20-90%, NVP-BEZ235 was 
clearly more potent than TAK-165 in both MDA-MB-231 
and MCF-7 cell lines. The equivalent concentrations 
of TAK-165 and NVP-BEZ235 for 50% cell survival for 
the MDA-MB-231 cell line were found to be 4.25 ± 0.23 
nM (95% CI: 3.79-4.76 nM) and 27.12±4.65 nM (95% 
CI: 18.50-39.74 nM), respectively. The corresponding 
EC50-values for the MCF-7 cell line emerged as 4.15 ± 
0.34 nM (95% CI: 3.48-4.95 nM) and 24.88 ± 2.26 nM 
(95% CI: 20.32-30.45 nM), respectively. 
Modulation of radiosensitivity by TAK-
165 and NVP-BEZ235
To evaluate the impact of inhibitor exposure on 
radiosensitivity, based on clonogenic cell survival, 
cell cultures were irradiated to 2 Gy immediately after 
administering TAK-165, NVP-BEZ235, or a combination 
of both inhibitors (Figure 3). In MDA-MB-231 cells 
(Figure 3A), inhibition of HER-2 with TAK-165 alone led 
to a small and insignificant radiosensitisation, with SF2 
decreasing from 0.59 ± 0.01 to 0.49 ± 0.05 (P=0.13, 
R2=0.48). This translated to about 20% increase in 
radiotoxicity (Table 1). In contrast, treatment of MCF-
7 and MCF-12A cells did not appear to affect cellular 
radiosensitivity at 2 Gy (Figures 3B and 3C and Table 
1). Inhibiting PI3K and mTOR activity with NVP-
BEZ235 significantly radiosensitised MDA-MB-231 and 
MCF-7 cells, but not the apparently normal MCF-12A 
cells (Figure 3 and Table 1). The resulting SF2-values 
were 0.32 ± 0.04 (P=0.0046, R2=0.89), 0.14 ± 0.02 
(P=0.02, R2=0.78) and 0.46 ± 0.05 (P=0.25, R2=0.57) 
for the MDA-MB-231, MCF-7 and MCF-12A cell lines, 
respectively. The corresponding modifying factors were 
1.84 ± 0.23, 1.64 ± 0.05 and 1.30 ± 0.21. Concomitant 
treatment with TAK-165 and NVP-BEZ235, significantly 
enhanced radiosensitivity in all cell lines (0.0002 ≤ P ≤ 
0.0183), yielding ~4-, ~3-, and ~7-fold reduction in cell 
survival in the MDA-MB-231, MCF-7 and MCF-12A cell 
lines, respectively (Table 1).
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Figure 1: Clonogenic cell survival curves for 3 human breast cell lines after 60Co γ-irradiation. Symbols repre-
sent the mean surviving fraction ± SE from three independent experiments. Standard errors are not transformed 
into a logarithmic scale.  Survival curves were obtained by fitting experimental data to the LQ model. 
Figure 2:  HER-2, PI3K and mTOR inhibitor toxicity in 3 human breast cell lines expressed as cell survival and 
plotted as a function of log(inhibitor concentration). Cell survival was determined by the colony assay, and data 
were fitted to a 4-parameter logistic equation. Data points are means±SE of 3 independent experiments.
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Discussion 
The phosphatase and tensin homolog (PTEN) 
which impedes PI3K/mTOR pathway activity, thereby 
sensitising cells to cytotoxic insult, is wildly expressed 
in all cell lines used here [16]. Therefore, the observed 
differences in radiosensitivity, as illustrated in Figure 
1, cannot be attributed to disparities in PTEN activity. 
While the more radioresistant MDA-MB-231 and MCF-
12A cell lines express wild-type PI3K, the radiosensitive 
MCF-7 cells are PI3K mutant [16,17]. This may explain 
the relatively high radiosensitivity in the latter cell line. A 
reduction in PI3K/mTOR signaling in MCF-7 cells due 
to the PI3K mutation can compromise their ability to 
recover from radiation-induced damage. 
It is demonstrated for MDA-MB-231 and MCF-7 cells 
that cytotoxicity of NVP-BEZ235 and TAK-165, based 
on clonogenic survival, is concentration-dependent 
(Figure 2). For NVP-BEZ235 treatment, the EC50-values 
of 4.25 and 4.15 nM obtained for MDA-MB-231 and 
MCF-7, respectively, are comparable with PI3K/mTOR 
inhibition data reported elsewhere for MDA-MB-231 
and the HER-2 amplified breast cancer cell lines BT474 
and MDA-MB-175-VII [16,17]. In contrast, significantly 
higher NVP-BEZ235 concentrations for 50% growth 
inhibition (IC50) ranging from 6-93 nM have emerged 
for many other breast cancer cell lines, with HER-2 
amplified cell lines tending to be more sensitive [16,18]. 
Interestingly, Brachmann et al. [18] demonstrated that 
doses of NVP-BEZ235 for 50% cell kill (LD50) for MDA-
MB-231 and MCF-7 cells can be ~87 and >20 000 nM, 
respectively. The disparity in toxicity noted here can be 
explained by the fact that cell growth and metabolic 
assays which extend over relatively short periods often 
tend to overestimate cell survival following cytotoxic 
treatment. Cell growth and metabolic assays are 
snapshots of cellular demise and may not adequately 
reflect residual cellular reproductive integrity as 
measured by the colony forming assay; and the resulting 
LD50-values can be unrealistically high. The similarity in 
NVP-BEZ235 toxicity in MDA-MB-231 and MCF-7 cells 
seems to suggest that NVP-BEZ235-induced cell death 
cannot be attributed to ER-mediation of PI3K activity, 
as the latter cell line is known to exhibit ER-dependent 
PI3K activity while the former does not [19]. Based 
on clonogenic cell survival, TAK-165 was generally 
less potent, with an EC50 of ~25-27 nM (Figure 2). All 
cell lines minimally express HER-2 [13,14], and the 
extensive concentration-dependent TAK-165 induced 
cytotoxicity observed here cannot be solely attributed 
to HER-2 alone. This finding is likely due to targeting 
of residual HER-2, as well as, other critical cellular 
factors. TAK-165 is a potent inhibitor of EGFR and the 
cell division cycle protein 2 homolog (Cdc2), which play 
a crucial role in cell-cycle progression. Perturbation of 
their activity with TAK-165 can lead to cellular demise 
during cell division. Cdc2 activity in MDA-MB-231 is 
intrinsically higher than that in MCF-7 [20], indicating 
a stronger dependence of the former cell line on Cdc2 
activity for cell cycle progression. Inhibiting Cdc2 and 
the residual HER-2 activity with TAK-165 can, therefore, 
be expected to be more toxic in MDA-MB-231 cells 
than in their MCF-7 counterparts. However, TAK-165 
concentrations used in the current study are much lower 
than those that are typically required to significantly 
suppress Cdc2 and EGFR activity [21]. At such high 
concentrations, TAK-165 has been shown to be ~4-fold 
more inhibitory than demonstrated here in a variety of 
cancer cell lines of bladder, kidney and prostate origin 
in which HER-2 expression ranged from weak to high 
[21]. 
In this presentation, it is demonstrated that treatment 
of all the three cell lines with TAK-165 yielded only 
6-20% radiosensitisation (Figure 3 and Table 1). This 
is not unexpected, as the cell lines express very low 
levels of HER-2 [14,15]. The role of HER-2 perturbation 
in radiosensitivity modulation should, therefore, be 
minimal. This is consistent with data reported elsewhere 
indicating that trastuzumab (a potent HER-2 inhibitor) 
had little or no effect on radiation-induced apoptosis in 
breast cancer cell lines that show low to no expression 
of HER-2 [22]. However, when cells were treated with 
the PI3K/mTOR inhibitor, significant radiosensitisation 
was seen in the MDA-MB-231 and MCF-7 cell lines, 
but not in the MCF-12A cell line (Figure 3 and Table 
1). These data cannot be explained in terms of PI3K 
status, as NVP-BEZ235 induced radiosensitisation 
was seen in the MDA-MB-231 (PI3K wild-type) and 
MCF-7 (PI3K mutant) cell lines, but not in the MCF-
12A (PI3K wild-type) cell line. The marked disparity 
between ~2-fold radiosensitisation observed here and 
the ~4-fold radiosensitisation reported elsewhere [23], 
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Figure 3: Clonogenic cell survival at 2 Gy (SF2) for 3 human breast cell lines after 60Co γ-irradiation: (A) MDA-
MB-231, (B) MCF-7, and (C) MCF-12A. Cells were irradiated without or in the presence of TAK-165 (HER-2 in-
hibitor) and NVP-BEZ235 (dual inhibitor of PI3K and mTOR), either administered singly or in combination. Bars 
represent the mean surviving fraction ± SE from three independent experiments. In comparison with SF2 without 
inhibitors: *0.005 < P ≤ 0.02; **P ≤ 0.005. 
might be due to differences in experiment design. The 
NVP-BEZ235 concentration of 100 nM used by Kuger 
and colleagues was ~6 times that used in the present 
study [23], and corresponds to NVP-BEZ235 doses 
at which cell survival levels should become very low 
if the residence time of the drug was over the entire 
colony forming period (Figure 2). Drug cytotoxicity 
strongly depends on residence time [24]. Also, delayed 
trypsinisation and re-plating of cells after drug and 
radiation treatment can significantly modify the extent 
to which the drugs modulate radiosensitivity.
Interestingly, although radiosensitisation by TAK-165 
was expectedly minimal, a 3- to 6-fold radiosensitisation 
emerged when cell cultures were pre-treated with a 
combination of TAK-165 and NVP-BEZ235 (Table 1). To 
interrogate any potential mode of interaction between 
the two inhibitors, the data presented in Figure 2 were 
used to construct median-effect plots, as illustrated 
in Figure 4, from which combination indices (CI) were 
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Figure 4: Median-effect plots for 2 human breast cell lines, treated with NVP-BEZ235 (circles and solid lines) 
and TAK-165 (squares and dashed lines), from toxicity data presented in Figure 2: (A) MDA-MB-231 and (B) MCF-
7. Transformed data were fitted to the function: log(fa/fu) = m×log(D) – m×log(Dm), where fa and fu are the affected 
and unaffected fractions of cells, respectively, and the coefficient m is an indicator of the shape of the inhibitor 
concentration-effect relationship (m=1, >1, and <1 indicate hyperbolic, sigmoidal, and flat-sigmoidal inhibitor con-
centration-effect curves, respectively), Dm is the median-effect concentration of inhibitor,  and D is the concen-
tration of inhibitor [25]. Horizontal dotted lines are the median-effect axes. For MDA-MB-231, the fitted m and Dm 
values were 1.78 and 7.28 nM, respectively, for NVP-BEZ235 (r=0.93); and 2.16 and 24.72 nM, respectively, for 
TAK-165 (r=0.95). The corresponding values for MCF-7 were 2.05 and 5.22 nM for NVP-BEZ235 (r=0.98); and 
2.18 and 20.51 nM for TAK-165 (r=0.95). The r-values were high, signifying a strong conformity of the data to the 
mass-action law [25]. Dm values were marginally lower than corresponding EC50-values.
estimated for the single inhibitor cocktail for the MDA-
MB-231 and MCF-7 cell lines [25]. CI-values of 0.72 
and 0.73 emerged for the MDA-MB-231 and MCF-7 
cell lines, respectively, indicating synergism for TAK-
165 and NVP-BEZ235 at the concentrations used here. 
This might explain the more than additive enhancement 
of radiosensitivity seen in all cell lines (Table 1). Of 
specific note is the ~7-fold radiosensitisation observed 
in the MCF-12A cell line when cells were pre-treated 
with inhibitor cocktail. It is not likely that the inhibitory 
activity of the TAK-165/NVP-BEZ235 cocktail is 
directed towards ER and PR, as radiosensitisation 
was higher in the ER-negative and PR-negative cell 
lines (MDA-MB-231 and MCF-12A) than the ER and 
PR overexpressing MCF-7 cell line [14,15]. The current 
findings seem to suggest that the activity of the TAK-
165/NVP-BEZ235 cocktail is specific for other targets, 
such as, EGFR which is often overexpressed by cells 
with compromised activity of HER-2, ER and PR [11]. 
The rank order of EGFR expression in the three cell 
lines is: MCF-7<MDA-MB-231<MCF-12A [14,15], 
and is consistent with the extent of radiation dose 
modification (Table 1). Therefore, EGFR is a likely 
target for a TAK-165/NVP-BEZ235 cocktail. The higher 
radiosensitisation seen in the intrinsically radioresistant 
immortalised mammary epithelial cell line (MCF-12A), 
following the cocktail treatment, might be an indication 
that concomitant use of cocktail and radiation could 
potentially elevate normal tissue toxicity and requires 
further evaluation. 
In conclusion, this study demonstrates that 
concomitant inhibition of HER-2, PI3K, and mTOR 
in human breast cancer cell lines with differing HER-
2, ER, PR, and EGFR expression levels results in 
significant radiosensitisation on the basis of clonogenic 
cell survival. Radiosensitisation is more prominent in 
ER- and PR-negative cells expressing higher levels of 
EGFR. These findings suggest that a cocktail of TAK-
165 and NVP-BEZ235 may have the potential for more 
effectively targeting triple-negative breast cancer cells, 
and provide the basis for further studies involving a 
larger panel of cell lines covering a wider range of HER-
2, ER, PR, and EGFR expression profiles.
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